<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 1999
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
COMMISSION FILE NO. 0-23659
VYSIS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 36-3803405
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER IDENTIFICATION NUMBER)
INCORPORATION OR ORGANIZATION)
3100 WOODCREEK DRIVE 60515-5400
DOWNERS GROVE, ILLINOIS (ZIP CODE)
(ADDRESS OF PRINCIPAL
EXECUTIVE OFFICES)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (630) 271-7000
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes /X/ No / /
Number of shares of Common Stock, par value $.001 per share, outstanding as
of August 2, 1999: 9,915,461
<PAGE>
VYSIS, INC.
FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 1999
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
----
<S> <C> <C>
PART I: FINANCIAL INFORMATION
ITEM 1: Financial Statements
Consolidated Balance Sheets
As of June 30, 1999 and December 31, 1998 ................. 2
Consolidated Statements of Operations
For the three months ended June 30, 1999 and 1998 ......... 3
Consolidated Statements of Operations
For the six months ended June 30, 1999 and 1998 ........... 4
Consolidated Statements of Comprehensive Operations
For the three months ended June 30, 1999 and 1998 ......... 5
Consolidated Statements of Comprehensive Operations
For the six months ended June 30, 1999 and 1998 ........... 6
Consolidated Statements of Cash Flows
For the six months ended June 30, 1999 and 1998 ........... 7
Notes to Consolidated Financial Statements ..................... 8
ITEM 2: Management's Discussion and Analysis of Financial Condition
and Results of Operations ..................................... 12
ITEM 3: Quantitative and Qualitative Disclosure About Market Risk ........ 19
PART II: OTHER INFORMATION
ITEM 1: Legal Proceedings ................................................ 20
ITEM 2: Changes in Securities and Use of Proceeds ........................ 20
ITEM 4: Submission of Matters to a Vote of Security Holders .............. 21
ITEM 6: Exhibits and Reports on Form 8-K ................................. 22
SIGNATURE ............................................................... 23
</TABLE>
1
<PAGE>
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
VYSIS, INC.
(AN INDIRECT SUBSIDIARY OF BP AMOCO P.L.C.)
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
(UNAUDITED)
<TABLE>
<CAPTION>
JUNE 30, DECEMBER 31,
1999 1998
-------- --------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents .................................................... $ 1,680 $ 4,672
Short-term investments ....................................................... 8,445 13,667
Accounts receivable, net ..................................................... 5,284 6,106
Current portion of long-term lease receivables ............................... 432 378
Inventories .................................................................. 2,797 2,487
Other current assets ......................................................... 1,298 782
-------- --------
Total current assets ................................................... 19,936 28,092
Property and equipment, net .................................................... 3,508 3,879
Investment ..................................................................... -- 562
Long-term lease receivables .................................................... 285 626
Other assets ................................................................... 1,728 1,884
-------- --------
Total assets ........................................................... $ 25,457 $ 35,043
-------- --------
-------- --------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt ............................................ $ 461 $ 553
Accounts payable and accrued liabilities ..................................... 7,611 9,475
Deferred revenue ............................................................. 742 966
-------- --------
Total current liabilities .............................................. 8,814 10,994
-------- --------
Long-term debt ................................................................. 230 523
-------- --------
Stockholders' equity:
Convertible Preferred Stock, $0.001 par value; 10,000,000 shares authorized:
Series A; 6,200,000 shares designated; none issued and outstanding at
June 30, 1999 and December 31, 1998 .................................... -- --
Series B; 553,126 shares designated; none issued and outstanding at
June 30, 1999 and December 31, 1998 .................................... -- --
Common stock, $0.001 par value; 35,000,000 shares authorized; 9,811,063 issued
and outstanding at June 30, 1999; 9,788,401 issued and outstanding
at December 31, 1998 ................................................... 10 10
Additional paid-in capital ................................................... 71,878 71,862
Deferred compensation ........................................................ (46) (81)
Unrealized gain on investment ................................................ -- 462
Cumulative translation adjustment ............................................ (507) (101)
Accumulated deficit .......................................................... (54,922) (48,626)
-------- --------
Total stockholders' equity ............................................. 16,413 23,526
-------- --------
Total liabilities and stockholders' equity ............................. $ 25,457 $ 35,043
-------- --------
-------- --------
</TABLE>
See notes to the consolidated financial statements.
2
<PAGE>
VYSIS, INC.
(AN INDIRECT SUBSIDIARY OF BP AMOCO P.L.C.)
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED JUNE 30,
---------------------------
1999 1998
------- -------
<S> <C> <C>
Revenues:
Product revenue ................................................ $ 6,354 $ 6,286
Grant and other revenue ........................................ 118 396
Legal settlement ............................................... -- 384
------- -------
Total revenues ........................................... 6,472 7,066
Cost of goods sold ............................................... 2,639 2,813
------- -------
Gross profit ..................................................... 3,833 4,253
------- -------
Operating expenses:
Research and development ....................................... 2,351 2,950
Selling, general and administrative ............................ 4,413 4,670
------- -------
Total operating expenses ................................. 6,764 7,620
------- -------
Loss from operations ............................................. (2,931) (3,367)
Interest income .................................................. 150 359
Interest expense ................................................. (17) (39)
------- -------
Net loss ......................................................... $(2,798) $(3,047)
------- -------
------- -------
Basic and diluted net loss per share ............................. $ (0.29) $ (0.31)
------- -------
------- -------
Shares used in computing basic and diluted net loss per share .... 9,808 9,700
</TABLE>
See notes to the consolidated financial statements.
3
<PAGE>
VYSIS, INC.
(AN INDIRECT SUBSIDIARY OF BP AMOCO P.L.C.)
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)
<TABLE>
<CAPTION>
SIX MONTHS ENDED JUNE 30,
-------------------------
1999 1998
-------- --------
<S> <C> <C>
Revenues:
Product revenue ................................................ $ 11,637 $ 10,845
Grant and other revenue ........................................ 279 888
Legal settlement ............................................... -- 384
-------- --------
Total revenues ........................................... 11,916 12,117
Cost of goods sold ............................................... 4,686 4,874
-------- --------
Gross profit ..................................................... 7,230 7,243
-------- --------
Operating expenses:
Research and development ....................................... 4,828 5,527
Selling, general and administrative ............................ 8,834 9,716
Restructuring expense .......................................... 541 --
-------- --------
Total operating expenses ................................. 14,203 15,243
-------- --------
Loss from operations ............................................. (6,973) (8,000)
Interest income .................................................. 370 572
Gain on sale of investment ....................................... 357 --
Interest expense ................................................. (50) (170)
-------- --------
Net loss ......................................................... $ (6,296) $ (7,598)
-------- --------
-------- --------
Basic and diluted net loss per share ............................. $ (0.64) $ (0.83)
-------- --------
-------- --------
Shares used in computing basic and diluted net loss per share .... 9,800 9,009
</TABLE>
See notes to the consolidated financial statements.
4
<PAGE>
VYSIS, INC.
(AN INDIRECT SUBSIDIARY OF BP AMOCO P.L.C.)
CONSOLIDATED STATEMENTS OF COMPREHENSIVE OPERATIONS
(IN THOUSANDS)
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED JUNE 30,
---------------------------
1999 1998
------- -------
<S> <C> <C>
Net loss ....................................... $(2,798) $(3,047)
Other comprehensive income (loss):
Cumulative translation adjustment ........ (123) 122
Unrealized holding loss on investment .... -- (190)
------- -------
Total other comprehensive loss ..... (123) (68)
------- -------
Comprehensive loss ............................. $(2,921) $(3,115)
------- -------
------- -------
</TABLE>
See notes to the consolidated financial statements.
5
<PAGE>
VYSIS, INC.
(AN INDIRECT SUBSIDIARY OF BP AMOCO P.L.C.)
CONSOLIDATED STATEMENTS OF COMPREHENSIVE OPERATIONS
(IN THOUSANDS)
(UNAUDITED)
<TABLE>
<CAPTION>
SIX MONTHS ENDED JUNE 30,
-------------------------
1999 1998
------- -------
<S> <C> <C>
Net loss ....................................... $(6,296) $(7,598)
Other comprehensive income (loss):
Cumulative translation adjustment ........ (406) 119
Unrealized holding loss on investment .... (105) (164)
Realized loss on investment .............. (357) --
------- -------
Total other comprehensive loss ..... (868) (45)
------- -------
Comprehensive loss ............................. $(7,164) $(7,643)
------- -------
------- -------
</TABLE>
See notes to the consolidated financial statements.
6
<PAGE>
VYSIS, INC.
(AN INDIRECT SUBSIDIARY OF BP AMOCO P.L.C.)
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(UNAUDITED)
<TABLE>
<CAPTION>
SIX MONTHS ENDED JUNE 30,
-------------------------
1999 1998
-------- --------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss ................................................................ $ (6,296) $ (7,598)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization ..................................... 868 1,364
Gain on sale of investment ........................................ (357) --
Stock compensation ................................................ 35 82
Changes in assets and liabilities:
Accounts receivable ......................................... 399 (1,759)
Inventories ................................................. (408) (28)
Other current assets ........................................ (504) 294
Lease receivables ........................................... 179 --
Other assets ................................................ 80 (180)
Accounts payable and accrued liabilities .................... (1,711) (281)
Deferred revenue ............................................ (189) (180)
-------- --------
Net cash used in operating activities ............................. (7,904) (8,286)
-------- --------
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from maturities of short-term investments ...................... 17,732 --
Proceeds from sale of investment ........................................ 457 --
Purchases of short-term investments ..................................... (12,510) (13,346)
Purchases of property and equipment ..................................... (384) (423)
Increase in other assets ................................................ (64) (102)
-------- --------
Net cash provided by (used in) investing activities ............... 5,231 (13,871)
-------- --------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from option plan exercises ..................................... 16 --
Proceeds from issuance of common stock .................................. -- 32,161
Increase in note payable--BP Amoco ...................................... -- 1,665
Expenses funded by BP Amoco ............................................. -- 153
Loan repayment to BP Amoco .............................................. -- (2,000)
Principal payments on long-term borrowings .............................. (272) --
-------- --------
Net cash provided by (used in) financing activities ............... (256) 31,979
Effect of exchange rate changes on cash .................................. (63) (8)
-------- --------
Net increase (decrease) in cash and cash equivalents ..................... (2,992) 9,814
Cash and cash equivalents at beginning of period ......................... 4,672 669
-------- --------
Cash and cash equivalents at end of period ............................... $ 1,680 $ 10,483
-------- --------
-------- --------
</TABLE>
See notes to the consolidated financial statements.
7
<PAGE>
VYSIS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 1--ORGANIZATION AND BUSINESS:
Vysis, Inc. ("Vysis" or the "Company") is a Genomic Disease Management
company that develops, commercializes and markets clinical products that provide
information critical to the evaluation and management of cancer, prenatal
disorders and other genetic diseases. Vysis currently markets five U.S. Food and
Drug Administration ("FDA") cleared or approved clinical products in addition to
distributing over 300 research products through its direct sales operations in
the United States and Europe and a worldwide distribution network covering 51
countries. The Company's wholly owned subsidiary, Gene-Trak Systems Industrial
Diagnostics Corporation, manufactures and markets food testing kits based on DNA
("Deoxyribonucleic Acid") probes.
The Company was incorporated in Delaware on April 18, 1991. The Company's
business represents the consolidation of multiple research units and programs of
the former Amoco Corporation. On December 31, 1998, Amoco Corporation merged
with the former British Petroleum Corporation, and as a result of the merger
became a wholly-owned subsidiary of BP Amoco p.l.c. As used herein, "BP Amoco"
refers to BP Amoco p.l.c. and its wholly owned subsidiaries. In 1994, BP Amoco
began consolidation of all of its medical diagnostic businesses and related
research under the Company. In March 1994, BP Amoco contributed to the Company
all of its genetic disease related assets, including the stock of Imagenetics
Incorporated (an Illinois corporation). Also in March 1994, BP Amoco contributed
all of its infectious disease related assets and the stock of Gene-Trak, Inc. to
the Company. Gene-Trak, Inc. had previously acquired certain infectious disease
related assets from Genzyme Corporation and BP Amoco, including all of the
interest in Gene-Trak Systems, a joint venture partnership for infectious
disease diagnostics established by BP Amoco and Integrated Genetics in 1986.
On February 10, 1998, the Company completed the initial public offering of
3 million shares of its Common Stock, par value $0.001 per share, at a price of
$12.00 per share (the "IPO"). The net proceeds of the IPO after deducting
expenses were approximately $32.1 million. Concurrent with the consummation of
the IPO, the Company issued 675,000 shares of Common Stock at $12.00 per share
to BP Amoco in exchange for a reduction of $8.1 million in the Company's note
payable to BP Amoco. As of August 2, 1999, BP Amoco beneficially owned
approximately 67 percent of the Company's outstanding Common Stock.
NOTE 2--FINANCIAL INFORMATION:
The unaudited interim consolidated financial statements of the Company have
been prepared pursuant to the rules and regulations of the Securities and
Exchange Commission. Accordingly, certain information and footnote disclosures
normally
8
<PAGE>
VYSIS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
(UNAUDITED)
included in financial statements prepared in accordance with generally accepted
accounting principles have been condensed or omitted. These interim consolidated
financial statements should be read in conjunction with the consolidated
financial statements and notes thereto included in the Company's Annual Report
on Form 10-K for the year ended December 31, 1998, and the Company's Quarterly
Report on Form 10-Q for the three months ended March 31, 1999, as filed with the
Securities and Exchange Commission.
In the opinion of management, the interim consolidated financial statements
reflect all adjustments necessary for a fair presentation of the interim
periods. All such adjustments are of a normal, recurring nature. Certain amounts
in fiscal 1998 have been reclassified to conform to the fiscal 1999
presentation. These changes had no impact on previously reported results of
operations or stockholders' equity. The results of operations for the interim
periods are not necessarily indicative of the results of operations to be
expected for a full year.
NOTE 3--RECENT ACCOUNTING PRONOUNCEMENT:
In June 1998, the Financial Accounting Standards Board issued SFAS No. 133
"Accounting for Derivative Instruments and Hedging Activities," effective for
all fiscal quarters of all fiscal years beginning after June 15, 1999. It
establishes accounting and reporting standards for derivative instruments and
for hedging activities. It requires that an entity recognize all derivatives as
either assets or liabilities in the statement of financial position and measure
those instruments at fair value. The Company anticipates that, due to its
current non-use of derivative instruments, the adoption of SFAS No. 133 will not
have a significant effect on the Company's results of operations or its
financial position.
NOTE 4--COMPOSITION OF BALANCE SHEET COMPONENT:
Inventories consisted of the following (in thousands):
<TABLE>
<CAPTION>
JUNE 30, DECEMBER 31,
1999 1998
---------- -----------
<S> <C> <C>
Raw materials and supplies ............. $1,339 $ 900
Finished goods ......................... 1,458 1,587
---------- -----------
$2,797 $2,487
---------- -----------
---------- -----------
</TABLE>
NOTE 5--LEASE RECEIVABLES AND LONG-TERM DEBT:
A wholly-owned foreign subsidiary of the Company has entered into certain
sales-type leasing transactions with customers. In order to comply with local
regulations with respect to such leasing transactions, the subsidiary must
borrow money and has assigned to the lender a security interest in the lease
receivables and related equipment. The debt is payable in monthly or quarterly
installments, matures over the next two years and bears
9
<PAGE>
VYSIS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
(UNAUDITED)
interest at rates ranging from 6.4% to 9.5%. The aggregate maturities of gross
lease receivables and long-term debt for the years ending June 30, are as
follows:
<TABLE>
<CAPTION>
GROSS LONG-TERM
RECEIVABLES DEBT
----------- ---------
<S> <C> <C>
2000 ................... $ 432 $ 461
2001 ................... 567 230
2002 ................... 50 --
------ ------
$1,049 $ 691
------ ------
------ ------
</TABLE>
The components of net lease receivables are as follows:
<TABLE>
<CAPTION>
JUNE 30,
1999
--------
<S> <C>
Gross lease receivables ................. $ 1,049
Allowance for doubtful accounts ......... (319)
Unearned income ......................... (13)
-------
$ 717
-------
-------
</TABLE>
NOTE 6--LEGAL SETTLEMENT:
During the second quarter of 1998, the Company recognized a $0.4 million
nonrecurring gain with respect to a settlement agreement with Oncor, Inc. which
ended a patent infringement suit brought by the Company, as exclusive licensee,
and its licensor.
NOTE 7--RESTRUCTURING:
On March 17, 1999, the Company's Board of Directors approved a
restructuring plan that resulted in the elimination of 20 positions within the
Company. The Company recorded a restructuring charge for severance costs of $0.5
million during the first quarter of 1999.
NOTE 8--GAIN ON SALE OF INVESTMENT:
During the first quarter of 1999, the Company sold its available-for-sale
investment of Incyte Pharmaceuticals, Inc. ("Incyte") common stock for $0.5
million, resulting in a gain on the sale of $0.4 million.
NOTE 9--SEGMENT AND GEOGRAPHIC INFORMATION:
The Company operates in one reportable business segment: the development,
manufacture and sale of genetic testing products. The Company's revenues by
product line for the three months and six months ended June 30, 1999 and 1998
are as follows (in thousands):
10
<PAGE>
VYSIS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED JUNE 30,
---------------------------
1999 1998
-------- --------
<S> <C> <C>
FDA/AFSSAPS approved clinical genetic testing
products ........................................ $ 1,042 $ 765
Research and other genetic testing products ...... 2,978 2,976
Genetic instrument products ...................... 1,363 1,568
Genetic research grants and license revenue ...... 118 396
Distributed laboratory products .................. 282 314
Food testing products ............................ 689 663
Legal settlement ................................. -- 384
-------- --------
Consolidated total revenues ...................... $ 6,472 $ 7,066
-------- --------
-------- --------
</TABLE>
<TABLE>
<CAPTION>
SIX MONTHS ENDED JUNE 30,
-------------------------
1999 1998
-------- --------
<S> <C> <C>
FDA/AFSSAPS approved clinical genetic testing
products ........................................ $ 1,923 $ 1,211
Research and other genetic testing products ...... 5,055 4,723
Genetic instrument products ...................... 2,831 3,099
Genetic research grants and license revenue ...... 279 888
Distributed laboratory products .................. 440 534
Food testing products ............................ 1,388 1,278
Legal settlement ................................. -- 384
-------- --------
Consolidated total revenues ...................... $ 11,916 $ 12,117
-------- --------
-------- --------
</TABLE>
The Company's revenues by geographic area based on location of customers
for the three months and six months ended June 30, 1999 and 1998 are as follows
(in thousands):
<TABLE>
<CAPTION>
THREE MONTHS ENDED JUNE 30,
---------------------------
1999 1998
-------- --------
<S> <C> <C>
United States .................................... $ 2,983 $ 3,073
Europe, Middle East and Africa ................... 3,798 4,416
Other ............................................ 553 556
Eliminations ..................................... (862) (979)
-------- --------
Consolidated total revenues ...................... $ 6,472 $ 7,066
-------- --------
-------- --------
</TABLE>
<TABLE>
<CAPTION>
SIX MONTHS ENDED JUNE 30,
-------------------------
1999 1998
-------- --------
<S> <C> <C>
United States .................................... $ 5,489 $ 5,176
Europe, Middle East and Africa ................... 7,516 7,612
Other ............................................ 1,167 1,051
Eliminations ..................................... (2,256) (1,722)
-------- --------
Consolidated total revenues ...................... $ 11,916 $ 12,117
-------- --------
-------- --------
</TABLE>
11
<PAGE>
VYSIS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
(UNAUDITED)
NOTE 10--SUBSEQUENT EVENTS:
During July 1999, the Company sold its cytogenetic imaging instrumentation
("Imaging") business, which represented nearly all of the Company's current
genetic instrument product line, to Applied Imaging Corp. ("AI") for a purchase
price of $2.35 million plus an additional consideration estimated to be
approximately $0.5 million for the purchase of certain Imaging component
inventory. Of the estimated $2.85 million in total consideration, the Company
has received $1.0 million in cash and $0.6 million of AI restricted common
stock. In addition, in accordance with the sale agreement, AI is obligated to
pay in cash an estimated $0.5 million during August 1999 for the inventory, $0.5
million in July 2000, and $0.25 million in January 2001. The Company estimates a
minimum gain on the sale of the Imaging business of approximately $1.1 million,
which excludes the future cash payments due in 2000 and 2001.
In addition, during July 1999, the Company acquired Aprogenex, Inc.'s
intellectual property portfolio for $250,000 plus the issuance of 80,291 shares
of the Company's common stock. The intellectual property portfolio included 12
United States patents and several licensed rights as well as the European and
Japanese counterpart patents and patent applications. The portfolio broadly
covers the identification of fetal cells in maternal blood by targeting m-RNA as
well as patents covering the use of oligonucleotides as Fluorescence IN SITU
Hybridization (FISH) probes.
The Company, BP Amoco and other parties were named as defendants in a
patent infringement suit brought by Gen-Probe Incorporated in the United
States District Court in the Southern District of California (San Diego).
During August 1999, the parties to the suit agreed to a settlement which will
result in dismissal of the action. The dismissal is subject to approval by
the Court. The settlement provides for an exchange of certain immunities and
licenses among the parties. No material amounts of cash will be paid by or
received by the Company upon completion of the settlement.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
The following discussion and analysis provides information which management
believes is relevant to an assessment and understanding of the Company's results
and financial condition. The discussion should be read in conjunction with the
audited consolidated financial statements of the Company and notes thereto,
which were included in the Company's Annual Report on Form 10-K for the year
ended December 31, 1998 as well as the financial statements of the Company and
notes thereto. This Quarterly Report on Form 10-Q contains certain statements
which describe the Company's beliefs concerning future business conditions and
the outlook for the Company based on currently available information. Whenever
possible, the Company has identified these "forward-looking" statements (as
defined in Section 21E of the Securities Exchange Act of 1934) by words such as
"anticipates", "believes", "estimates", "expects", and similar
12
<PAGE>
VYSIS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS--(CONTINUED)
expressions. These forward-looking statements are subject to risks and
uncertainties which could cause the Company's actual results, performance and
achievements to differ materially from those expressed in or implied by these
statements. These risks and uncertainties include, but are not limited to,
the following: competition; compliance by the Company with regulatory
requirements; the ability of the Company to successfully market and sell its
products and equipment; delays in the acceptance and adoption rates for the
Company's clinical products; the Company's ability to manufacture products in
sufficient quantities; the Company's ability to maintain intellectual
property protection for its proprietary products, to defend its existing
intellectual property rights from challenges by third parties, and to avoid
infringing intellectual property rights of third parties; and the extent to
which the clinicians or laboratories using the Company's products are able to
obtain third-party reimbursement.
OVERVIEW
Vysis is a leading genomic disease management company that develops,
commercializes and markets clinical products that provide information critical
to the evaluation and management of cancer, prenatal disorders and other genetic
diseases. The Company currently markets clinical products cleared by the U.S.
Food and Drug Administration ("FDA") and the Agence Francaise de Securite
Sanitaire des Produits de Sante ("AFSSAPS") (formerly the French Agence du
Medicament, or ADM), a line of research products, and instruments for genetic
analysis. During March 1998, the Company received registration from the AFSSAPS
to market throughout Europe the AneuVysion(TM) EC Assay for Down Syndrome and
other chromosomal disorders associated with mental retardation and birth
defects. During June 1999, the Company received registration from the AFSSAPS to
market CEP(R) 8 and CEP(R) 12 DNA Probe Kits, and has a pending application for
CEP X/Y, for use as adjuncts to standard cytogenetic analysis to identify and
enumerate the presence of chromosomes X and Y in bone marrow and chromosomes 8
and 12 in blood specimens, thus aiding in the diagnosis and treatment of
leukemia patients. The Company's PathVysion(TM) HER-2 DNA probe kit was approved
by the FDA in December 1998 for the assessment of the HER-2 gene status in node
positive Stage II breast cancer patients and for the prediction of the
therapeutic outcome of using adriamycin based chemotherapy in breast cancer
patients. Vysis currently markets five FDA cleared or approved clinical
products, including PathVysion(TM) HER-2, the U.S. versions of CEP X/Y, CEP 8
and CEP 12 and AneuVysion(TM), which received 510(k) clearance by the FDA during
1997, and over 300 research products. The Company has direct sales operations in
the United States and Europe, a marketing partnership in Japan with Fujisawa
Pharmaceutical Co., and a worldwide distribution network.
RESULTS OF OPERATIONS
Product revenue for the three months and six months ended June 30, 1999 was
$6.4 million and $11.6 million, respectively, an increase of $0.1 million, or
1%, and $0.8
13
<PAGE>
VYSIS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS--(CONTINUED)
million, or 7%, in comparison to the three months and six months ended June
30, 1998, respectively. Grant and other revenue for the three months and six
months ended June 30, 1999 was $0.2 million and $0.3 million, respectively,
which represented a decrease of $0.7 million and $1.0 million as compared to
the respective prior year periods. As a result, total revenues for the three
months and six months ended June 30, 1999 were $6.5 million and $11.9
million, respectively, a decrease of $0.6 million and $0.2 million for the
three months and six months ended June 30, 1998, respectively. The product
revenue increases for the three months and six months ended June 30, 1999 are
primarily attributable to a $0.3 million, or 36%, and $0.7 million, or 59%,
increase in worldwide shipments of FDA/AFSSAPS approved clinical genetic
testing products ("Clinical"), offset by a $0.2 million, or 13%, and $0.3
million, or 8%, decrease in genetic instrument sales for the three months and
six months ended June 30, 1999, respectively. In addition, research and other
genetic testing products ("Research") revenue for the three months ended June
30, 1999 increased slightly over the 1998 second quarter, and increased $0.3
million, or 7%, for the six months ended June 30, 1999 in comparison to the
second half of 1998. The increase in Clinical sales is primarily due to sales
in the U.S. of the Company's PathVysion(TM) HER-2 DNA Probe Kit that was
approved by the FDA in December 1998 and European sales of the Company's
prenatal products. The minimal increase in Research sales for the second
quarter is primarily the result of the Company changing its European
distribution of former Oncor, Inc. products from utilizing a distributor, who
purchased products in quantities that lasted approximately six months, to
selling directly to customers through the Company's direct sales force.
During April 1998 the former European distributor purchased from the Company
$0.8 million of Research products, which represented approximately a
six-month supply of such products. This significant 1998 purchase has been
offset in 1999 by continued worldwide growth of Research products. The
decline in instrument sales reflects the continuing weakness of the overall
instrument market. As described in Note 10 to the Consolidated Financial
Statements, the Company sold during July 1999 its imaging instrumentation
business, which currently represents nearly all of its existing genetic
instrument business. The decrease in grant and other revenue for the three
months and six months ended June 30, 1999 was primarily due to the completion
of two United States Department of Commerce research grants in February 1998
and July 1998 as well as receiving $0.4 million of nonrecurring other revenue
during the second quarter of 1998 related to a settlement agreement with
Oncor.
Cost of goods sold for the three months and six months ended June 30, 1999
were $2.6 million and $4.7 million, respectively, representing a decrease of
$0.2 million, or 6%, and $0.2 million, or 4%, from the respective prior year
periods. The decline in cost of goods sold resulted in gross profit as a
percentage of product revenue increasing to 58.5% and 59.7% for the three months
and six months ended June 30, 1999, respectively, from 55.2% and 55.1% for the
three months and six months ended June 30, 1998, respectively. While product
revenue increased for the three months and six months ended June 30, 1999, cost
of goods sold decreased and the resulting product gross profit increased by $0.2
million, or 7%, and $1.0 million, or 16%, over the respective prior year
14
<PAGE>
VYSIS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS--(CONTINUED)
periods, primarily due to a continuing improvement in product mix as the
aforementioned growth in the higher margin Clinical products represented a
higher percentage of total product sales versus the comparable prior year
periods.
Operating expenses for the three months and six months ended June 30,
1999 were $6.8 million and $14.2 million, a decrease of $0.9 million, or 11%,
and $1.0 million, or 7%, as compared to the three months and six months ended
June 30, 1998, despite the six months ended June 30, 1999 including a first
quarter restructuring charge of $0.5 million associated with the elimination
of 20 positions within the Company. Research and development expenses of $2.4
million and $4.8 million for the three months and six months ended June 30,
1999 represented a decrease of $0.6 million and $0.7 million as compared to
the respective prior year periods. These decreases were primarily
attributable to lower software development costs and resulting savings from
the elimination of certain positions in connection with the Company's
restructuring during the first quarter of 1999. Selling, general and
administrative expenses of $4.4 million and $8.8 million for the three months
and six months ended June 30, 1999, respectively, represented a decrease of
$0.3 million, or 6%, and $0.9 million, or 9%, respectively, over the prior
year periods. The 1999 second quarter decrease is the result of a $0.4
million reduction in selling expenses primarily due to a reduction in bad
debt expense, offset by a $0.1 million increase in general and administrative
expense, while the reduction in expenses for the first half of 1999 is
primarily the result of a $0.9 million reduction in general and
administrative expenses primarily due to lower litigation expense in
comparison to the respective prior year periods.
Interest income for the three months and six months ended June 30, 1999 was
$0.2 million and $0.4 million, respectively, representing a decline of $0.2
million for both of the comparable prior year periods as a result of utilizing
the proceeds from the February 10, 1998 IPO. Interest expense for the six months
ended June 30, 1999 decreased $0.1 million as a result of a note payable with BP
Amoco remaining outstanding until the completion of the Company's IPO.
The gain on sale of investment for the six months ended June 30, 1999 was
$0.4 million that resulted from the $0.5 million sale of the Company's
investment in Incyte common stock.
INCOME TAXES
Prior to the completion of the Company's IPO, the results of operations
were included in the consolidated income tax returns of BP Amoco; accordingly,
the domestic net operating losses through February 10, 1998 have been utilized
by BP Amoco in its consolidated income tax returns and are not available to
offset the Company's future taxable income. Subsequent to the IPO, the Company
is filing separate federal income tax returns. As the Company was in a loss
position for the six months ended June 30, 1999, no federal provision is
recorded. For state income taxes, the Company's results of operations
15
<PAGE>
VYSIS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS--(CONTINUED)
will continue to be included with BP Amoco, due to its 67 percent ownership
interest in the Company, in those states where required by state tax law.
Under state tax laws in a number of states, including Illinois (the state in
which much of the Company's business is taxed), the Company is required by
law to be included in BP Amoco's unitary state tax returns as long as BP
Amoco owns or controls 50 percent or more of the voting equity. For unitary
state filings, the tax sharing agreement with BP Amoco requires BP Amoco to
pay the Company the incremental tax savings, if any, received by BP Amoco as
a result of including the Company's results of operations in such filings.
The agreement also requires the Company to pay BP Amoco the incremental tax
liability, if any, incurred by BP Amoco as a result of including the
Company's results of operations in such filings. The Company and BP Amoco are
currently unable to estimate the amount of state income tax benefit to be
received by the Company as a result of its operating losses for the three
months and six months ended June 30, 1999 and, accordingly, no state tax
benefit is recorded. For state income taxes in non-unitary states, the
Company has not recorded any benefit as a result of its loss position for the
three months and six months ended June 30, 1999.
A full valuation allowance has been provided for all deferred tax assets
(net of liabilities) at June 30, 1999 as management does not consider
realization of such amounts more likely than not.
LIQUIDITY AND CAPITAL RESOURCES
Net cash used in operating activities for the six months ended June 30,
1999 was $7.9 million, a decrease of $0.4 million over the prior year, driven
primarily by the $1.3 million reduction in operating losses during the first
half of 1999, offset by a $0.5 million reduction in depreciation and
amortization and a $0.5 million increase in working capital requirements as
compared to the prior year.
Net cash provided by investing activities for the six months ended June 30,
1999 was $5.2 million, resulting primarily from maturities of short-term
investments. During the prior year, the $13.9 million of net cash flows used in
investing activities resulted primarily from the purchase of short-term
investments with a portion of the net proceeds from the February 1998 IPO.
Net cash used in financing activities for the six months ended June 30,
1999 was $0.3 million, an increase of $32.2 million from the prior period
primarily due to receiving the net proceeds from the IPO during February 1998.
At June 30, 1999, the Company had cash, cash equivalents and short-term
investments of $10.1 million and an accumulated deficit of $54.9 million. Since
its inception, the Company has experienced negative cash flows from operations.
In order to preserve the Company's cash position and to reduce cash used in
operating activities, the Company's Board of Directors approved during March
1999 a restructuring plan that resulted in the elimination of 20 positions in
the U.S., representing a 12 percent reduction
16
<PAGE>
VYSIS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS--(CONTINUED)
of the U.S. work force, thereby reducing ongoing annual cash expenditures by
an estimated $1.6 million. The Company recorded a restructuring charge for
severance costs of $0.5 million during the first quarter of 1999. During July
1999, the Company sold its cytogenetic imaging instrumentation ("Imaging")
business, which represented nearly all of the Company's current genetic
instrument product line, to Applied Imaging Corp. ("AI") for a purchase price
of $2.35 million plus an additional consideration estimated to be
approximately $0.5 million for the purchase of certain instrumentation
component inventory. Of the estimated $2.85 million in total consideration,
the Company has received
$1.0 million in cash and $0.6 million of AI restricted common stock. In
addition, in accordance with the sale agreement, AI is obligated to pay in cash
an estimated $0.5 million during August 1999 for the inventory, $0.5 million in
July 2000, and $0.25 million in January 2001.
The Company believes that its current cash and short-term investment
position, and the interest to be earned thereon, will be sufficient to fund the
Company's operations into 2000. The Company's estimate of the time period for
which cash funds will be adequate to fund its operations is a forward looking
estimate subject to risks and uncertainty, and actual results may differ
materially. The Company's requirements for additional capital will depend on
many factors, including growth in product revenue; payments received under
existing and potential collaborative agreements; the availability of government
research grant payments; the progress of the Company's collaborative and
independent research and development projects; the costs of preclinical and
clinical trials for the Company's products; the prosecution, defense and
enforcement of patent claims and other intellectual property rights; and the
development of manufacturing, sales and marketing capabilities. To the extent
capital resources, including payments from existing and possible future
collaborative agreements and grants, together with the net proceeds of the IPO
are insufficient to meet future capital requirements, the Company will have to
raise additional funds to continue the development of its technologies. There
can be no assurance that such funds will be available on favorable terms, or at
all. To the extent that additional capital is raised through the sale of equity
or convertible debt securities, the issuance of such securities could result in
dilution to the Company's shareholders. If adequate funds are not available, the
Company may be required to curtail operations or to obtain funds through
entering into collaborative agreements on unattractive terms. The Company's
inability to raise capital as and when needed would have a material adverse
effect on the Company's business, financial condition and results of operations.
READINESS FOR THE YEAR 2000
Many currently installed computer systems and software products are coded
to accept only two digit entries in the date code field. As the Year 2000
approaches, these code fields will need to accept four digit entries to
distinguish years beginning with "19" from those beginning with "20". As a
result, computer systems and/or software products used by many companies may
need to be upgraded to comply with such Year 2000 requirements.
17
<PAGE>
VYSIS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS--(CONTINUED)
The Company is in the process of evaluating the Year 2000 readiness of
the software products sold by the Company ("Products"), the information
technology systems used in its operations ("IT Systems"), and its non-IT
Systems, such as manufacturing/facility related equipment and other systems
that could impact the operations of the Company. The Company currently
anticipates that this project will consist of the following phases: (i)
identification of all Products, IT Systems, and non-IT Systems; (ii)
assessment of repair or replacement requirements; (iii) repair or
replacement; (iv) testing where necessary; (v) implementation; and (vi)
creation of contingency plans in the event of Year 2000 failures.
The Company completed the review of all current versions of its Products
and believes that all Products are Year 2000 compliant. With respect to IT
Systems, the Company has developed a plan to make its systems Year 2000
compliant and began implementation of the plan during the first quarter of 1999.
The Company's current IT Systems related to manufacturing are already Year 2000
compliant. To implement the other IT Systems modules for Year 2000 compliance
requires an upgrade to a more current version of the existing software, which
was supplied to the Company at no charge. However, the Company has elected to
use this opportunity to upgrade all modules to the most current version offered
by the software vendor. The Company currently expects this project to be
substantially complete by the third quarter of 1999. Once installed and
operational, the Company will assess the need to develop contingency plans
related to these IT Systems. The Company does not expect this project to have a
significant impact on its information technology ("IT") budget or other
non-related IT projects, as discussed below. The Company will continue to
implement IT systems with strategic value and has started to implement a new
European management information system which is expected to also be completed in
1999.
In the area of non-IT Systems, the Company relies, both domestically and
internationally, upon various vendors, government agencies, research
institutions, utility companies, telecommunications service companies, delivery
service companies, and other material and service providers who are outside of
the Company's control. There is no assurance that such parties will not suffer a
Year 2000 business disruption, which could have a material adverse effect on the
Company's financial condition and results of operations. The Company has
initiated formal communications with significant vendors to determine the extent
of which the Company is vulnerable to those third parties' failure to remediate
their own Year 2000 issues. The Company is requesting that third party vendors
represent their products and services to be Year 2000 compliant and that they
have a program to test for Year 2000 compliance. However, the response of those
third parties is beyond the Company's control. The Company has received a
significant number of responses and is currently evaluating and following up
where necessary in order to better assess any potential Year 2000 compliance
issues. This evaluation is currently ongoing and is expected to be complete by
early September. To the extent that the Company does not receive adequate
responses during this final evaluation and follow-
18
<PAGE>
VYSIS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS--(CONTINUED)
up period, it is prepared to develop contingency plans, with completion of
these plans scheduled for no later than October 1999. At this time, the
Company cannot estimate the additional cost, if any, that might develop from
such contingency plans. With respect to the manufacturing/facility related
equipment and other systems, the Company has assessed the majority of these
equipment and systems and believes that they are Year 2000 compliant. The
remaining equipment and systems will be assessed by the end of September.
To date, the Company has incurred expenditures in connection with Year 2000
compliance issues, including updating its IT System modules to the most current
version available, aggregating $68,000 of expense and $53,000 of capitalized
costs. Absent a significant Year 2000 compliance deficiency, the Company
currently estimates that the remaining cost to complete its Year 2000 compliance
programs, including updating its IT System modules to the most current version
available, will be less than $150,000 of expense and $75,000 of capitalized
costs.
Breakdowns in the Company's IT Systems and non-IT Systems, such as its
manufacturing application software and the computer chips embedded in its plant
equipment, as well as other Year 2000-related problems such as disruptions in
the delivery of materials, power, heat or water to the Company's facilities,
could prevent the Company from being able to manufacture and ship its products.
If the Company were to fail to correct a material Year 2000 problem, its normal
business activities and operations could be interrupted. Such interruptions
could materially and adversely affect the Company's results of operations,
liquidity and financial condition.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company is subject to market risk associated with changes in foreign
currency exchange rates and interest rates. The Company's exchange rate risk is
limited to its operations in England, Germany, France and Italy. The exchange
rate risk is mitigated through local purchases for the majority of their
expenditures. The Company's primary foreign currency exchange rate risk results
from the foreign operations' intercompany purchases of clinical and research
products as well as certain instrument system components. The majority of the
intercompany purchases are not expected to be repaid in the foreseeable future
as these operations have required more working capital as a result of their
significant growth. Sales throughout the rest of the world are denoted in U.S.
dollars. The Company does not believe that the impact from foreign currency
exchange rate fluctuations will have a material impact on its financial
statements. The net impact of foreign exchange activities on earnings was
immaterial for the three months and six months ended June 30, 1999 and 1998. The
foreign currency translation loss included in shareholders' equity resulting
from the translation of the financial statements of the Company's international
subsidiaries into U.S. dollars increased by $0.1 million and $0.4 million for
the three months and six months ended June 30, 1999, respectively, due to the
19
<PAGE>
VYSIS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS--(CONTINUED)
strengthening of the U.S. dollar against the functional currency of the
Company's international subsidiaries. Interest rate exposure is primarily
limited to the $8.4 million of short-term investments owned by the Company. Such
securities are debt instruments which generate interest income for the Company
on excess cash balances. The Company does not actively manage the risk of
interest rate fluctuations; however, such risk is mitigated by the relatively
short term, less than 12 months, nature of these investments.
The Company does not consider the present rate of inflation to have a
significant impact on its business.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Reference is made to Item 3. Legal Proceedings in the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 1998 and the
Company's Quarterly Report on Form 10-Q for the period ending March 31, 1999
for discussion of litigation matters relating to the Company. The Company, BP
Amoco and other parties were named as defendants in a patent infringement
suit brought by Gen-Probe Incorporated in the United States District Court in
the Southern District of California (San Diego). During August 1999, the
parties to the suit agreed to a settlement which will result in dismissal of
the action. The dismissal is subject to approval by the Court. The settlement
provides for an exchange of certain immunities and licenses among the
parties. No material amounts of cash will be paid by or received by the
Company upon completion of the settlement.
The Company and other parties were named as defendants in a suit pending in
California state court brought by David Kohne. The suit alleged that the Company
and the other defendants maliciously prosecuted two earlier lawsuits involving
patents issued to David Kohne. However, the Company has since been dropped from
the suit without prejudice and is no longer a defendant in the suit.
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
In connection with the IPO (see Note 1 of the Notes to Consolidated
Financial Statements for further discussion), the Company received net proceeds
of $32.1 million from the sale of 3,000,000 shares of its Common Stock. From the
closing date of the IPO, February 10, 1998, to June 30, 1999, the Company used
such net offering proceeds as follows (in millions):
20
<PAGE>
VYSIS, INC.
PART II. OTHER INFORMATION--(CONTINUED)
<TABLE>
<CAPTION>
<S> <C>
Purchase of short-term investments and cash equivalents $ 10.1
Repayment of note payable-BP Amoco 2.0
Acceleration of product development, expansion of sales
and marketing capabilities and funding of increased
working capital requirements and ongoing operations 20.0
-------
Total $ 32.1
-------
-------
</TABLE>
Each of these amounts is a reasonable estimate of the application of the
net offering proceeds. This use of proceeds does not represent a material
change in the use of proceeds described in the Prospectus for the IPO. Other
than the repayment of a note payable to BP Amoco in the amount of $2 million,
none of such amounts (with the exception of salaries and directors' fees and
working capital advances to affiliates incurred in the ordinary course of
business) represented direct or indirect payments to (i) directors or
officers of the Company or their associates, (ii) persons owning 10% or more
of any class of equity securities of the Company or (iii) affiliates of the
Company.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
On or about May 28, 1999, proxy materials were distributed to all
shareholders of record as of the close of business on May 3, 1999. The results
of the shareholders' votes were disclosed at the 1999 annual meeting of
shareholders (the "Annual Meeting") of the Company which convened on June 30,
1999.
At the Annual Meeting, the following individuals were elected by the votes
indicated as directors of the Company until the 2000 Annual Meeting and their
successors have been elected and qualified:
<TABLE>
<CAPTION>
NOMINEE FOR WITHHELD
------------------- --------- --------
<S> <C> <C>
William M. Bartlett 9,347,023 14,540
John L. Bishop 9,260,135 101,428
Kenneth L. Melmon 9,347,023 14,540
Anthony J. Nocchiero 9,344,218 17,345
Walter R. Quanstrom 9,344,723 16,840
Frank J. Sroka 9,344,523 17,040
Richard C. Williams 9,336,023 25,540
</TABLE>
The other item acted upon at the Annual Meeting was the adoption of the
1999 Outside Directors Stock Option Plan (the "Plan") described in the proxy
materials. The Plan was approved by the following vote:
<TABLE>
<CAPTION>
FOR AGAINST ABSTAINED
--------- ------- ---------
<S> <C> <C> <C>
9,253,781 93,868 13,914
</TABLE>
21
<PAGE>
VYSIS, INC.
PART II. OTHER INFORMATION--(CONTINUED)
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
EXHIBITS
Exhibit 2.1*, Asset Purchase, License, and Distribution Agreement between
the Company and Applied Imaging Corp. dated July 16, 1999.
The schedules and exhibits to the foregoing agreement, which are listed on
page (iv) thereto, have not been filed herewith. The schedules and exhibits will
be furnished supplementally to the Securities and Exchange Commission upon
request.
Exhibit 27.1, Financial Data Schedule (included only in the electronic
filing of this document).
* Confidential treatment requested for portions of this exhibit.
REPORTS ON FORM 8-K
There were no Form 8-K reports filed during the quarter.
22
<PAGE>
VYSIS, INC.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VYSIS, INC.
Date: August 16, 1999 By: /s/ ALFRED H. ELLSWORTH
------------------------------------
Name: Alfred H. Ellsworth
TITLE: VICE PRESIDENT, FINANCE
AND CHIEF ACCOUNTING OFFICER
23
<PAGE>
Confidential Treatment Requested by
Vysis, Inc.
EXHIBIT 2.1
ASSET PURCHASE, LICENSE, AND DISTRIBUTION AGREEMENT
MARKED, REDACTED COPY
<PAGE>
ASSET PURCHASE, LICENSE, AND DISTRIBUTION AGREEMENT
BY AND BETWEEN
VYSIS, INC.
AND
APPLIED IMAGING CORP.
JULY 16, 1999
<PAGE>
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
<S> <C>
ARTICLE I. DEFINITIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1
ARTICLE II. PURCHASE AND SALE. . . . . . . . . . . . . . . . . . . . . . . . . . . .3
2.1 Sale and Purchase of Assets . . . . . . . . . . . . . . . . . . . . . . .3
2.2 Assumption of Liabilities . . . . . . . . . . . . . . . . . . . . . . . .4
ARTICLE III. PURCHASE PRICE; CLOSING . . . . . . . . . . . . . . . . . . . . . . . .4
3.1 Purchase Price. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4
3.2 Inventory Purchase. . . . . . . . . . . . . . . . . . . . . . . . . . . .4
3.3 Closing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5
3.4 Transaction Taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . .5
3.5 Form of Delivery. . . . . . . . . . . . . . . . . . . . . . . . . . . . .6
ARTICLE IV. REPRESENTATIONS AND WARRANTIES OF VYSIS. . . . . . . . . . . . . . . . .6
4.1 Organization, Standing and Power. . . . . . . . . . . . . . . . . . . . .6
4.2 Authority . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7
4.3 Consents and Approvals. . . . . . . . . . . . . . . . . . . . . . . . . .7
4.4 Litigation, Claims, Violations. . . . . . . . . . . . . . . . . . . . . .7
4.5 Intellectual Property . . . . . . . . . . . . . . . . . . . . . . . . . .7
4.6 Assigned Properties . . . . . . . . . . . . . . . . . . . . . . . . . . .7
4.7 [*] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8
4.8 Digital Scientific. . . . . . . . . . . . . . . . . . . . . . . . . . . .8
ARTICLE V. REPRESENTATIONS AND WARRANTIES OF AI. . . . . . . . . . . . . . . . . . .8
5.1 Organization, Standing and Power. . . . . . . . . . . . . . . . . . . . .8
5.2 Authority . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8
5.3 Consents and Approvals. . . . . . . . . . . . . . . . . . . . . . . . . .8
ARTICLE VI. DISTRIBUTION COVENANTS . . . . . . . . . . . . . . . . . . . . . . . . .9
6.1 Excluded Agreements . . . . . . . . . . . . . . . . . . . . . . . . . . .9
6.2 Continuation of Distributor Agreements. . . . . . . . . . . . . . . . . .9
6.3 [*] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9
6.4 European Sales Agency . . . . . . . . . . . . . . . . . . . . . . . . . .9
6.5 Selected Product Financial Information. . . . . . . . . . . . . . . . . .9
6.6 Excluded in Transfer. . . . . . . . . . . . . . . . . . . . . . . . . . .9
6.7 Supply of Filters and Filter Holders. . . . . . . . . . . . . . . . . . 10
6.8 Orders/Technical Service Support. . . . . . . . . . . . . . . . . . . . 10
6.9 Sales Transition. . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
6.10 Override Fee. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
</TABLE>
-i-
<PAGE>
<TABLE>
<CAPTION>
<S> <C>
ARTICLE VII. LICENSE COVENANTS . . . . . . . . . . . . . . . . . . . . . . . . . . 11
7.1 Grant of Exclusive License. . . . . . . . . . . . . . . . . . . . . . . 11
7.2 Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
7.3 Covenant Not to Sue . . . . . . . . . . . . . . . . . . . . . . . . . . 13
ARTICLE VIII. COVENANTS WITH RESPECT TO MANUFACTURING. . . . . . . . . . . . . . . 13
8.1 Training. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
8.2 Manufacturing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
8.3 [*] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
8.4 Access to Research Records and Technical Information. . . . . . . . . . 15
8.5 Contracts, Licenses and Service Agreements. . . . . . . . . . . . . . . 15
8.6 Assumption of Contract Obligations. . . . . . . . . . . . . . . . . . . 15
8.7 Employment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
ARTICLE IX. GENERAL COVENANTS. . . . . . . . . . . . . . . . . . . . . . . . . . . 16
9.1 Access and Rights of Inspection . . . . . . . . . . . . . . . . . . . . 16
9.2 Further Assurances. . . . . . . . . . . . . . . . . . . . . . . . . . . 16
9.3 Claims Handling . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
9.4 [*] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
9.5 Confidentiality Regarding Information of Business . . . . . . . . . . . 17
9.6 Covenant Not to Compete . . . . . . . . . . . . . . . . . . . . . . . . 17
9.7 Compatibility of Reagents . . . . . . . . . . . . . . . . . . . . . . . 17
ARTICLE X. SURVIVAL OF REPRESENTATIONS AND WARRANTIES;
INDEMNIFICATION; ARBITRATION . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
10.1 Indemnification by Vysis. . . . . . . . . . . . . . . . . . . . . . . . 17
10.2 Indemnification by AI . . . . . . . . . . . . . . . . . . . . . . . . . 18
10.3 Procedure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
10.4 Indemnity Limit . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
10.5 Disclaimer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
10.6 Survival of Warranties. . . . . . . . . . . . . . . . . . . . . . . . . 19
10.7 Limitation of Liability . . . . . . . . . . . . . . . . . . . . . . . . 19
ARTICLE XI. MISCELLANEOUS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
11.1 Successors; Assignability . . . . . . . . . . . . . . . . . . . . . . . 19
11.2 Costs and Expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
11.3 Other Agreements Superseded; Waiver and Modification, Etc . . . . . . . 19
11.4 Overdue Payments. . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
11.5 Notices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
11.6 Parties in Interest . . . . . . . . . . . . . . . . . . . . . . . . . . 20
11.7 Governing Law; Jurisdiction . . . . . . . . . . . . . . . . . . . . . . 20
11.8 Fair Construction/Difference in Facts . . . . . . . . . . . . . . . . . 20
11.9 Captions, References, Date. . . . . . . . . . . . . . . . . . . . . . . 20
11.10 Severability. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
11.11 Counterparts. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
11.12 Recovery of Litigation Costs. . . . . . . . . . . . . . . . . . . . . . 20
</TABLE>
ii
<PAGE>
<TABLE>
<CAPTION>
<S> <C>
11.13 Relationship of the Parties . . . . . . . . . . . . . . . . . . . . . . 21
11.14 Brokerage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
11.15 Publicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
11.16 Arbitration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
11.17 Sole Remedy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
</TABLE>
iii
<PAGE>
SCHEDULES AND EXHIBITS
SCHEDULES
1 Product List
2 Assigned Contracts
3 Tangible Assets (including Inventory)
4 License Agreements
5 Service Agreements
6 Trademarks and Copyrights
7 Purchase Price Allocation
8 Exceptions to Representation and Warranties
9 Assumed Warranties and Service Contracts
10 Filters and Filter Holders
11 Employees
12 Sales Analysis Data
EXHIBITS
A Stock Issuance Agreement
B Bill of Sale and General Assignment of Assets
C European Sales Agency Agreement
D Override Fee Calculation
E Quality Criteria for SpectraVysion and PathVysion, and Other Vysis
Trademarked Products
F [*]
G Press Announcement
H Sales Lead Form
I Electronic Transfer Guidelines
-iv-
<PAGE>
ASSET PURCHASE, LICENSE, AND DISTRIBUTION AGREEMENT
This Asset Purchase, License and Distribution Agreement (this
"AGREEMENT"), effective as of July 16, 1999, is made by and between Vysis, Inc.
("VYSIS"), a Delaware corporation with its principal place of business at 3100
Woodcreek Drive, Downers Grove, Illinois, and Applied Imaging Corp. ("AI"), a
Delaware corporation with its principal place of business at 2380 Walsh Avenue,
Building B, Santa Clara, California. Vysis and AI are sometimes referred to
herein as the "Parties."
RECITALS
WHEREAS, Vysis desires to sell certain assets of its cytological digital
imaging business to AI on the terms and conditions herein, and AI desires to
purchase such assets; and
WHEREAS, the Parties desire to enter into license and distribution
arrangements in connection with the sale of the assets;
NOW, THEREFORE, in consideration of the above and the mutual promises and
covenants set forth below, Vysis and AI agree as follows:
ARTICLE 1 DEFINITIONS
For the purposes of this Agreement the following definitions shall apply:
"AFFILIATE" of a party means, with respect to any party, any other person
or entity that, directly or indirectly, controls, is controlled by or is under
common control with, that party; provided, however, that in each case any such
other person or entity shall be considered to be an Affiliate only during the
time such control exists. For purposes of this definition, "control"
(including, with correlative meaning, the terms "controlled by" and "under
common control with") means the possession, directly or indirectly, of the power
to direct and/or cause the direction of the management and policies of such
party, whether through the ownership of voting securities, by contract or
otherwise.
"BOOKS AND RECORDS" means copies of specific books and records related to
any assets sold by Vysis hereunder, including, without limitation, product lists
with list prices, selling prices, and cost of goods sold on a country-by-country
basis, all financial records, books, ledgers, supplier lists, customer and
marketing lists or databases, marketing plans, management plans, distribution
and reseller materials, advertising materials, and manuals, insofar as such
items relate to the Business. Books and Records which relate solely to the
Business shall be the subject of title transfer from Vysis to AI. Books and
Records which do not solely relate to the Business transferred hereunder shall
be the subject of an unlimited right granted by Vysis to AI for AI to use such
Books and Records in furtherance of the Business, provided that Vysis shall have
the right to first redact any information, including information related to
Vysis' reagent business, not relevant to AI's conduct of the Business contained
in such nonexclusive Books and Records.
<PAGE>
"BUSINESS" means Vysis' FISH and brightfield cytological digital
imaging system and software business (including those products comprising the
QUIPS genetic imaging products marketed and under development by Vysis shown
in SCHEDULE 1 in the Cytogenetic and Pathology Field, as defined below).
"CLOSING" is defined in Section 3.2.
"CONTRACT" means any written contract, agreement, commitment, note, bond,
lease, mortgage, guaranty, license or any other written contractual obligation
or commitment that is listed on SCHEDULE 2, attached hereto and made a part of
this Agreement by this reference.
"CYTOGENETIC AND PATHOLOGY FIELD" means the field of clinical and
research applications for both human and non-human species involving testing of
tissue, blood and cellular samples.
"EXCLUDED ASSETS" means any and all assets, both tangible and intangible,
of Vysis that (i) are not listed on SCHEDULES 1, 2, 3, 4, 5 OR 6, including,
without limitation thereto any receivable or, any tangible asset used in the
manufacture of a reagent product, or (ii) are not expressly granted to AI under
Article 7, such as for example and without limitation thereto any patent right
covering fluorescence in situ hybridization assays.
"INTELLECTUAL PROPERTY RIGHTS" means, collectively, all Patents, Trade
Secrets, Copyrights, moral rights, trade names, Trademarks, rights in trade
dress, rights in biological materials and all other intellectual property rights
and proprietary rights, whether arising under the laws of the United States or
any other state, country or jurisdiction, including without limitation all
rights or causes of action for infringement or misappropriation of any of the
foregoing. "PATENTS" mean all patents rights and all right, title and interest
in all letters patent or equivalent rights and applications for letters patent
or rights, industrial and utility models, industrial designs, patents of
importation, patents of addition, certificates of invention and any indicia of
invention ownership issued or granted by any Governmental Entity, including
without limitation any reissue, extension, division, continuation or
continuation-in-part applications throughout the world. "TRADE SECRETS" mean
all right, title and interest in all trade secrets and trade secret rights
arising under the applicable common law, state law, federal law or laws of
foreign countries. "COPYRIGHTS" mean all copyright rights and all other
literary property and author rights, and all right, title and interest in all
copyrights, copyright registrations, certificates of copyright and copyrighted
interests throughout the world. "TRADEMARKS" mean all trademark and service
mark rights arising under the applicable common law, state law, federal law and
laws of foreign countries, all right, title and interest in all trademarks,
service marks, trademark and service mark applications and registrations and
trademark and service mark interests throughout the world.
"INVENTORY" means all items listed on SCHEDULE 3, attached hereto and
made a part of this Agreement by this reference, under the headings "Inventory
Items", "Demonstration Equipment" or "Service Equipment" subject to review and
acceptance by AI.
"LICENSE AGREEMENTS" means the license agreements listed on SCHEDULE 4
attached hereto and made a part of this Agreement by this reference.
-2-
<PAGE>
"LIEN" means liens, pledges, claims, charges, security interests and
other restrictions or encumbrances of any nature whatsoever, except for (i)
liens for current taxes not yet delinquent or which are being contested in
good faith by appropriate proceedings, (ii) statutory liens imposed by law
which are incurred in the ordinary course of business for obligations not yet
due including to carriers, warehousemen, laborers and materialmen, and (iii)
deposits in connection with workers' compensation, unemployment insurance,
bids, trade contracts, bonds or leases created in the ordinary course of
business.
"OTHER ASSETS" means manufacturer's or vendor's warranties or guarantees
relating to any asset acquired hereunder, claims (excluding any Vysis receivable
based claim or patent infringement claim) against third parties relating to any
asset acquired by AI hereunder, and any other tangible assets used exclusively
in the Business or any tangible assets reasonably necessary for AI to operate
the Business, which are owned by Vysis as of the Closing Date.
"STOCK ISSUANCE AGREEMENT" means the agreement between Vysis and AI as
of the date hereof regarding the AI common stock issuance to Vysis as partial
consideration for Vysis' performance of this Agreement, included herein as
EXHIBIT A attached hereto and made a part of this Agreement by this reference.
"SERVICE CONTRACTS" means the contracts listed on SCHEDULE 5 attached
hereto and made a part of this Agreement by this reference.
"TANGIBLE ASSETS" means all of the property listed on SCHEDULE 3 attached
hereto and made a part of this Agreement by this reference.
"TRANSFERRED COPYRIGHTS" means all of the unregistered copyrights listed
on SCHEDULE 6 attached hereto and made a part of this Agreement by this
reference.
"TRANSFERRED TRADEMARKS" means all of the Trademark registrations listed
on SCHEDULE 6 attached hereto and made a part of this Agreement by this
reference.
ARTICLE 2 PURCHASE AND SALE
2.1 SALE AND PURCHASE OF ASSETS. Subject to the terms and conditions
contained in this Agreement, Vysis hereby sells, assigns, transfers, and
delivers to AI all of Vysis' right, title, and interest in and to all assets
listed on SCHEDULES 1 THROUGH 6 hereof along with any Other Assets and the Books
and Records of the Business (collectively, the "ACQUIRED ASSETS") to AI on the
Closing Date on the terms and conditions as set out herein.
(a) INVENTORY. AI shall initially purchase, at net book value,
the Inventory identified by AI on SCHEDULE 3 consistent with the terms of
Section 3.2 below. All Inventory desired by AI on SCHEDULE 3 will be shipped to
AI's facility within 45 days of the Closing in accordance with AI's
instructions. Vysis shall, within 10 days of the Closing Date, update
SCHEDULE 3 which shall include demonstration units, and then AI shall have 10
days thereafter to choose which of those units will be purchased by AI.
-3-
<PAGE>
(b) RIGHTS UNDER CONTRACTS. All of Vysis' rights under any
contract, agreement, license, plan or arrangement relating primarily or
exclusively to the Business identified in SCHEDULE 1 shall be transferred to
AI. It is the intent of the parties hereto that any new customer orders
received by Vysis arising out of the operation of the Business following the
Closing Date be transferred to AI. Included on SCHEDULE 1 is (i) a list as
of June 30, 1999 of all outstanding written customer orders, purchase orders,
and other customer commitments from Vysis' customers of the Business, and
(ii) the names of all customers of the Business, which list will be updated
as of the Closing and provided to AI.
(c) BOOKS AND RECORDS. Copies of all Books and Records shall
be delivered in hard copy and/or electronic form, as assembled by Vysis subject
to prior review by AI personnel.
2.2 ASSUMPTION OF LIABILITIES. AI is not assuming any liabilities
of Vysis, except those listed on SCHEDULE 9. AI shall not be responsible for,
is not assuming, and shall have no liability whatsoever for any other liability
or obligation.
ARTICLE 3 PURCHASE PRICE; CLOSING
3.1 PURCHASE PRICE. The purchase price payable by AI to Vysis as
full consideration for the sale, assignment, transfer, and delivery by Vysis
to AI of the Acquired Assets, and the assumption by AI of the Assumed
Liabilities, AI, on the terms and conditions set forth herein, shall be
$2,350,000 (the "PURCHASE PRICE") paid as follows:
(a) CASH PAYMENTS. AI shall pay to Vysis One Million Seven
Hundred Fifty Thousand Dollars ($1,750,000) in three installments: One Million
Dollars ($1,000,000) by wire transfer at Closing (the "INITIAL PAYMENT");
subject to Section 8.3, Five Hundred Thousand Dollars ($500,000) on the one year
anniversary of the Closing; and subject to Section 8.3, Two Hundred-Fifty
Thousand Dollars ($250,000) on the eighteenth month anniversary of the Closing.
The two installments to be paid on the one year and eighteen month anniversary
of the Closing Date, respectively, shall each bear interest at the annual rate
of seven percent (7%), due and payable at the time the installment is due,
subject to Section 8.3.
(b) STOCK ISSUANCE. AI shall issue to Vysis Six Hundred
Thousand Dollars ($600,000) of AI Common Stock, par value $0.001, with the
number of shares of AI Common Stock determined by using the average closing
price for AI Common Stock on the NASDAQ National Market for the twenty (20)
trading days before and including the Closing Date. A certificate representing
such shares of AI Common Stock shall be issued to Vysis within 10 days of the
Closing pursuant to the Stock Issuance Agreement.
(c) CONTINGENCY FOR FAILURE OF CONSIDERATION. If AI does not
make any of the payments called for in Section 3.1 when due, Vysis may request
that AI make such payment. If AI does not make such payment within thirty (30)
days of Vysis' written request, Vysis shall be entitled to revoke the licenses
granted to AI under Section 7.1 and/or exercise its rights under this Agreement
to collect the payments owed, including termination of the noncompete covenants
contained herein.
3.2 INVENTORY PURCHASE. AI shall pay to Vysis in U.S. Dollars the net
book value of the Inventory identified by AI in SCHEDULE 3 up to Five Hundred
Thousand Dollars ($500,000) within
-4-
<PAGE>
forty-five (45) days of the Closing by wire transfer. In regards to any
additional Inventory identified by AI on SCHEDULE 3 in excess of the $500,000
net book value limit (including demonstration units), AI shall make payment
to Vysis within one hundred-eighty (180) days of the Closing by wire transfer.
3.3 CLOSING.
(a) DELIVERY. The closing of the purchase and sale of the
Acquired Assets and the consummation of the other transactions contemplated
hereby shall be held at the offices of Vysis' Downers Grove, Illinois facility,
at 1:00 p.m. (local time), on July 16, 1999 (the "CLOSING") or at such other
date, time and place not to be later than July 30, 1999, unless AI and Vysis
shall have agreed in writing (the date of the Closing is hereinafter referred to
herein as the "CLOSING DATE").
(b) CLOSING DELIVERIES. At the Closing, AI shall deliver the
Initial Payment against delivery by Vysis of such transfer documents relating to
the sale and transfer of the Acquired Assets as AI shall reasonably request,
including, without limitation, the Bill of Sale and General Assignment of Assets
in the form attached hereto as EXHIBIT B. At the Closing, Vysis shall put AI
into full possession and enjoyment of all the Acquired Assets, and AI shall be
fully and solely responsible for and perform when due or discharge all of the
Assumed Liabilities. With respect to Books and Records, generally, it is
understood that (i) Books and Records related to SCHEDULES 1 TO 9 shall be
delivered by Vysis to AI upon Closing, (ii) other Books and Records that relate
solely to the Business shall be delivered by Vysis to AI within thirty (30) days
of the Closing Date, and (iii) the Books and Records which do not solely relate
to the Business transferred hereunder shall be delivered by Vysis to AI within
ninety (90) days of the Closing Date. With respect to the SpectraVysion source
code to be transferred electronically under this Agreement, as detailed in
EXHIBIT I hereto, it is understood between the Parties that such source code has
been integrated with Vysis' GenoSensor source code, which AI agrees shall not be
used by AI for array imaging. At any time and from time to time after the
Closing, at the request of AI and without further consideration, Vysis shall
execute and deliver such further instruments of sale, transfer, conveyance,
assignment, and confirmation and take such actions as is reasonably necessary to
transfer, convey, and assign to AI (or such wholly owned subsidiary as AI may
designate), and to confirm AI's title to or interest in, the Acquired Assets, to
put AI in actual possession and operating control thereof, and to assist AI in
exercising all rights with respect thereto. With respect to the PathVysion
source code to be electronically transferred under this Agreement, a working
copy of the PathVysion software shall be delivered on the Closing Date and the
PathVysion source code shall be transferred as soon as practicable after such
source code has been given to Vysis. Upon request by AI after December 31,
1999, Vysis shall use its reasonable efforts to obtain such code from Digital
Scientific, Ltd.
3.4 TRANSACTION TAXES.
(a) SALES TAX. AI shall be responsible for any and all sales
taxes required to be paid in connection with the sale of the Acquired Assets.
(b) ALLOCATION OF CONSIDERATION. AI and Vysis will allocate
the Purchase Price among the Acquired Assets (the "ALLOCATION") in accordance
with SCHEDULE 7 to be attached to this Agreement at or prior to the Closing in a
form mutually agreeable to the parties. No party will take a
-5-
<PAGE>
position on any federal or state tax return, before any governmental agency
charged with the collection of any income tax, or in any judicial proceeding
that is in any way inconsistent with the Allocation.
3.5 FORM OF DELIVERY.
(a) MASTER COPY/SOURCE CODE. Vysis shall electronically
deliver on the Closing Date to AI's facility in Santa Clara, California,
subject to the limitations contained in Section 3.3(b) above, (i) the Master
Copy and (ii) a copy of the Source Code of all of the Vysis Systems and
Software Products listed on SCHEDULE 1, except for the PathVysion source code.
(b) TRADEMARK ASSIGNMENT. Vysis shall deliver to AI promptly
after the Closing Date executed assignments of the Trademark registrations and
applications listed on SCHEDULE 6, all in a form reasonably acceptable to AI.
(c) MANUFACTURING RECORDS. Vysis shall deliver to AI promptly
after the Closing Date a copy of the manufacturing and quality assurance
specifications and procedures used by Vysis in the manufacture of the Systems
and Software Products listed on SCHEDULE 1. Upon AI's request, Vysis will
provide AI's representatives access upon reasonable advance notice and during
normal business hours to all of the original product manufacturing records for
the installed base of the Business.
(d) ADVERTISING AND PROMOTIONAL MATERIALS. Upon the Closing
Date, Vysis, shall have available, and within one week of the Closing Date,
Vysis shall send to AI, all master copies, proofs and electronic source images
of the advertising and promotional materials developed for support of the QUIPS
products along with all copies of currently approved promotional materials which
shall include the delivery of those parts of any website maintained by Vysis
which is relevant to the transferred Business, and the right to use relevant
portions of the 1999-2000 Product Catalog. The Parties agree that with respect
to the foregoing, Vysis shall be allowed to retain sufficient copies of the
relevant advertising and promotional materials in order to continue to service
its European customers as contemplated by this Agreement, or any ancillary
agreement, as well as a sufficient number of copies of materials necessary for
Vysis' reagent business.
(e) DELIVERY COSTS. All costs and liability for the
shipment and physical delivery of any Acquired Assets and any intangible assets
shall initially be Vysis' responsibility as follows: Items to be delivered to
AI's designated facility will be shipped F.O.B. AI's facility, with costs of
transportation and insurance to be repaid to Vysis by AI. Risk of loss to all
items will belong to Vysis until delivery to AI's facility. AI shall have the
right to physically inspect all tangible assets at Vysis' facility, at the time
of inventory evaluation and again immediately prior to shipment to AI.
ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF VYSIS
Vysis represents and warrants to AI the following:
4.1 ORGANIZATION, STANDING AND POWER. Vysis is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Delaware. Vysis has the corporate power to own its properties and to carry on
its business as now being conducted.
-6-
<PAGE>
4.2 AUTHORITY. Vysis has all requisite corporate power and authority
to enter into this Agreement, the Stock Issuance Agreement and the European
Sales Representative Agreement (the "AGREEMENTS") and to perform its obligations
hereunder and thereunder and to consummate the transactions contemplated hereby
and thereby. The execution and delivery of the Agreements and the consummation
of the transactions contemplated hereby have been duly authorized by all
necessary corporate action on the part of Vysis, including any necessary action
by shareholders. The Agreements have been duly executed and delivered by Vysis,
and, assuming the valid execution and delivery of the Agreements by AI, the
Agreements constitute valid and binding obligations of Vysis, enforceable in
accordance with their terms, except as such enforcement may be limited by
applicable bankruptcy, insolvency, reorganization or other similar laws relating
to or affecting the enforcement of creditors' rights generally and by principles
of equity regarding the availability of remedies.
4.3 CONSENTS AND APPROVALS. The execution, delivery and performance
of this Agreement and the Stock Issuance Agreement by Vysis will not (a) violate
any provision of the Certificate of Incorporation or the Bylaws of Vysis; (b)
require any filing with, or permission, consent or approval of, or the giving of
any notice to, any U.S. governmental entity by Vysis, other than the FDA (and
any such required FDA filing will be made promptly by Vysis), or (c) violate any
statute, ordinance, rule, regulation, order or decree of any governmental entity
applicable to Vysis or by which any of its properties or assets may be bound; or
(d) result in a violation or breach of, constitute (with or without the giving
of notice or lapse of time or both) a default, give rise to any right of
termination under, or result in the creation of any Lien on the assets
transferred hereunder to AI.
4.4 LITIGATION, CLAIMS, VIOLATIONS. That, as of the Closing Date,
there is no action, suit, proceeding or investigation relating to the Business
pending in any court or before any arbitrator or U.S. or foreign governmental
entity or, to the knowledge of Vysis, threatened against Vysis or the operation
of the Business. That as of the Closing Date, Vysis has not received any
written notice from the U.S. FDA concerning any violation of FDA regulations in
its operation of the Business.
4.5 INTELLECTUAL PROPERTY. That as of the Closing Date Vysis does not
own or control any U.S. or foreign patent application with claims relating
solely to cytological digital imaging technology, except as set forth on
SCHEDULE 8, attached hereto. That as of the Closing Date Vysis does not own any
copyright registration, pending or issued in any jurisdiction, relating to the
Business. That, except as set out in SCHEDULE 8, as of the Closing Date, it has
the unencumbered right to grant the licenses granted in Section 7.1. That,
except as set forth on SCHEDULE 8, as of the Closing Date, Vysis has not
received notice from any entity or person of any conflict or potential conflict
by the Systems and Software Products listed on SCHEDULE 1 or the Trademarks
listed on SCHEDULE 6 with the Intellectual Property of any third party. That,
except as set forth on SCHEDULE 8, as of the Closing Date, SCHEDULE 4 lists all
material licenses by which Vysis licenses from third parties any rights related
to the Systems and Software Products listed on SCHEDULE 1. That, except as set
forth on SCHEDULE 8, as of the Closing Date, all Trademarks owned or controlled
by Vysis and used in the Business are listed on SCHEDULE 6.
4.6 ASSIGNED PROPERTIES. Vysis has good and marketable title to the
Tangible Assets, free and clear of all Liens.
-7-
<PAGE>
4.7 [*]. Except for third party codes embedded in [*] under
license, no third party has any claim or right of ownership over the [*]
system being developed by Vysis and governed by Section 8.3 of this
Agreement, and the [*]system when completed will be free and clear of any
third party right to title over the [*] system. Vysis warrants that the [*]
source code when delivered to AI will not contain any third party source
code, unless a license for such code can be passed through to AI or does not
prohibit AI's commercialization and distribution of [*] in digital imaging
systems. Vysis agrees to deliver to AI with the completed [*] system a list
of all third party code included in the [*]system. Vysis further agrees not
to include in the [*] system any royalty bearing code without AI's prior
written consent.
4.8 DIGITAL SCIENTIFIC. Vysis represents and warrants that its
agreement with Digital Scientific, Ltd. ("DSL"), which agreement is
addressed herein in Section 7.2, does not grant to DSL any claim or rights to
SpectraVysion system or software or the [*] system or software.
ARTICLE 5 REPRESENTATIONS AND WARRANTIES OF AI
AI represents and warrants to Vysis the following:
5.1 ORGANIZATION, STANDING AND POWER. AI is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Delaware. AI has the corporate power to own its properties and to carry on its
business as now being conducted.
5.2 AUTHORITY. AI has all requisite corporate power and authority
to enter into this Agreement, the Stock Issuance Agreement and the European
Sales Representative Agreement (the "AGREEMENTS") and to perform its
obligations hereunder and thereunder and to consummate the transactions
contemplated hereby and thereby. The execution and delivery of the
Agreements and the consummation of the transactions contemplated hereby have
been duly authorized by all necessary corporate action on the part of AI.
The Agreements have been duly executed and delivered by AI, and, assuming the
valid execution and delivery of this Agreement by Vysis, the Agreements
constitute valid and binding obligations of AI, enforceable in accordance
with their terms except as such enforcement may be limited by applicable
bankruptcy, insolvency, reorganization or other similar laws relating to or
affecting the enforcement of creditors' rights generally and by principles of
equity regarding the availability of remedies.
5.3 CONSENTS AND APPROVALS. The execution, delivery and
performance of this Agreement and the Stock Issuance Agreement by AI will not
(a) violate any provision of the Articles of Incorporation or the Bylaws of
AI; (b) require any filing with, or permission, consent or approval of, or
the giving of any notice to, any U.S. governmental entity by AI; (c) violate
any statute, ordinance, rule, regulation, order or decree of any governmental
entity applicable to AI or by which any of its properties or assets may be
bound; or (d) result in a violation or breach of, constitute (with or without
the giving of notice or lapse of time or both) a default, give rise to any
right of termination under, or result in the creation of any Lien upon AI or
any of its property that would materially interfere with AI's performance of
its obligations hereunder.
-8-
<PAGE>
ARTICLE 6 DISTRIBUTION COVENANTS
6.1 EXCLUDED AGREEMENTS. AI acknowledges that none of Vysis'
distributor agreements outside of the United States are being transferred, by
assignment or otherwise, to AI hereunder.
6.2 CONTINUATION OF DISTRIBUTOR AGREEMENTS. Within sixty (60) days
after the Closing Date, AI shall specify in writing which of Vysis' non-U.S.
distributor agreements (except for Japan and for those in Europe which are
governed by Sections 6.3 and 6.4 hereof), that AI wishes to continue to
distribute the Systems and Software Products transferred hereunder. For
those distributor agreements which AI will not continue, it shall notify
Vysis, and Vysis will notify the particular distributor that the Systems and
Software Products are being withdrawn from the distributor agreement. For a
period of not more than thirty (30) days, or such greater time as may be
required by any local laws which might govern the distributor agreement in
question, following the date of Vysis' notification of the product
withdrawal, AI shall continue to fulfill any orders for the Systems and
Software Products placed by the discontinued distributors provided payment is
made in accordance with AI's practices. For those distributor agreements
that AI wishes to continue, AI agrees to fulfill all product orders placed
under such distributor agreements and to use commercially reasonable efforts
to negotiate a distribution arrangement directly with the particular
distributor. Vysis will cooperate with AI in these negotiations. AI shall
not have any liability to terminated distributors under the existing
agreement they have with Vysis.
6.3 [*]. AI agrees to continue to fulfill all product orders
placed pursuant to Vysis' distribution agreement with [*] in [*] for the
current transferred Systems and Software Product line for as long as AI
continues manufacture and distribution of such product line. Except for any
Assumed Liabilities and products shipped after the Closing Date, AI shall not
have any liability to [*] under Vysis' current agreement with [*]. If [*]
elects to discontinue the transferred Systems and Software Product line, then
AI shall use reasonable commercial efforts to have its [*] representatives
offer revenue earning service to [*]'s former customers with respect to
Systems and Software Product line.
6.4 EUROPEAN SALES AGENCY. Vysis and AI will enter into the European
Sales Representative Agreement, attached hereto as EXHIBIT C, under which Vysis
will act as AI's exclusive sales agent (allowing in certain countries for AI to
also cooperatively promote and sell to customers through AI employees) for all
of AI's CytoVysion products, including those transferred to AI hereunder, for
the territory specified in the European Sales Representative Agreement.
6.5 SELECTED PRODUCT FINANCIAL INFORMATION. Vysis shall provide to AI
in SCHEDULE 12, at Closing, selected financial information on instrumentation
sales by certain customers and countries reflecting net sales value, cost of
goods sold and gross margin and supporting component composition for selected
sales in Europe. A copy of supporting component composition of each U.S.
instrument sale for the first six months of 1999 will be provided to AI five (5)
days after closing.
6.6 EXCLUDED IN TRANSFER. AI acknowledges that Vysis' assets,
including some portion of the inventory and the vendor supply agreement,
relating to imaging filters and filter holders, listed on SCHEDULE 10, attached
hereto, that are obtained from a third party vendor and are specified for use
-9-
<PAGE>
with the Systems and Software Products listed in SCHEDULE 1, are not included
in the assets transferred to AI hereunder, and that Vysis will continue to
sell imaging filters and filter holders as part of its reagent business and
maintain certain filter and filter holder inventory not transferred to AI.
It is the intent of the parties that AI will be the primary vendor of filters
and filter holders, and that Vysis as a service to its customers will
continue to sell filters and filter holders solely related to its reagent
sales.
6.7 SUPPLY OF FILTERS AND FILTER HOLDERS. Vysis agrees to give AI the
right to buy direct from Vysis' current third party supplier AI's requirements
for Vysis filters listed on SCHEDULE 10 for its continuation of the Business
acquired from Vysis. With respect to any new Vysis proprietary filters not
listed on SCHEDULE 10 which might come into use in conjunction with new product
development by Vysis, Vysis agrees (i) to provide to AI, sixty (60) to ninety
(90) days prior to marketing any such product, the technical information about
the new required filter, and (ii) to give to AI the right to obtain such filters
at Vysis' cost in a timely manner such that AI will be in a position to market
such filters at the time which coincides with the launch of the new product.
For non-proprietary filters, Vysis will assist AI in obtaining a supply of such
filters[*] For proprietary filters, Vysis will use reasonable commercial
efforts to ensure that AI receives an uninterrupted supply of such filters from
Vysis' same third party source at Vysis' cost. [*] AI shall have the right,
unrestricted in any way be Vysis, to sell the filters obtained under this
Section 6.7.
6.8 ORDERS/TECHNICAL SERVICE SUPPORT.
(a) After the Closing Date, Vysis shall use best efforts to
ensure that all communication from third parties related exclusively or
primarily to the Business will be forwarded immediately to AI, and will
transfer immediately to AI all orders for the Systems and Software Products
listed on SCHEDULE 1 that are received after the Closing Date.
(b) For a period of sixty (60) days after the Closing Date,
Vysis, at its expense, will dedicate two full-time U.S. technical service
employees, chosen at Vysis' discretion, to supporting AI's performance of the
Business. Such employee shall have previously worked in technical service
support for the Business.
(c) In addition to the personnel allocated in subsection (b)
above, for a period of sixty (60) days after the Closing Date, Vysis will, at
AI's expense, make its U.S. based personnel with knowledge of the Business
available to AI as reasonably requested by AI on at least 48 hours' notice, to
assist AI in the transition of the Business. AI shall pay all out-of-pocket
travel costs and expenses of Vysis' personnel who travel pursuant to such
requests. Vysis will provide, at AI's expense, telephone technical support to
back up AI's customer support and service personnel for sixty (60) days after
the Closing Date.
(d) EUROPE. For sixty (60) days past the Closing Date, Vysis
agrees to continue to perform all technical service support for the Systems and
Software Products listed in SCHEDULE 1 in Europe. AI shall be responsible for
all technical service in Europe thereafter.
(e) EXPANDED AI FIELD SERVICE SUPPORT. Vysis and AI agree to
review and negotiate a technical service agreement under which AI would supply
all of Vysis' requirements for
-10-
<PAGE>
field service support for VP-2000 and GenoSensor product lines. Neither
party shall be obligated by this Agreement to enter into an expanded
technical service agreement.
6.9 SALES TRANSITION.
(a) Upon the Closing Date, Vysis shall deliver to AI copies
of its customer lists, customer contacts, price lists and sales leads of the
Business. Vysis will provide AI with reasonable access during normal
business hours to any of its sales records relating to the Business; provided
that Vysis shall have the right to redact any information from such records
which relates to other parts of Vysis' business.
(b) For a period of sixty (60) days after the Closing Date,
Vysis shall make available, at Vysis' sole cost and expense, the East-Coast
and Mid-West U.S. Instrument Sales Representatives up to half-time and the
West-Coast U.S. Instrument Sales Representative on a full-time basis to
assist in the transition to AI of the sales activities of the Business. AI
will make an offer of employment to the West-Coast Sales Representative as
soon as practicable after the Closing Date. Such employees shall have
previously worked in sales for the Business in the capacities indicated.
(c) Promptly after the Closing Date, Vysis and AI shall each
post a notice acceptable to the other party of the transfer of the Business to
AI in its Web Site product catalog and shall provide a hypertext link to the
other's website.
(d) Vysis and AI will cooperate in AI's marketing and sales of
digital imaging products in the Cytogenetics and the Pathology Fields, with
Vysis notifying AI of any U.S. and Canadian sales leads its sales
representatives may develop on the form attached hereto as EXHIBIT H. For any
sales made by AI as a result of such leads, AI agrees to pay Vysis a "finders
fee" of one-half percent (0.5%) of the net selling price, which Vysis will pass
through in its entirety to the Vysis salesperson who generated the lead.
(e) Upon the Closing Date, Vysis agrees to transfer to AI a
complete listing of all Vysis imaging instrumentation customers worldwide. Such
list will include all Vysis account/customer numbers, account and primary
contact names, mailing and street addresses, phone, fax and e-mail contact
information formatted as a Microsoft Excel spreadsheet.
6.10 OVERRIDE FEE. AI will pay Vysis a [*] commission on sales
(excluding micrometastasis applications) that exceed AI's specific sales goals
within the U.S. territory as specified on EXHIBIT D hereto, which fee shall be
paid until the first commercial sales by Vysis of any automated scanning and
imaging system or integrated imaging system as defined in Section 7.1 (e)(ii)
and Section 7.1(e)(i), respectively, from any source sold into a Pathology lab.
ARTICLE 7 LICENSE COVENANTS
7.1 GRANT OF EXCLUSIVE LICENSE.
(a) Subject to the terms and conditions in this Agreement,
Vysis hereby grants to AI, and AI hereby accepts, a worldwide, paid-up,
transferable license, with right to sublicense, to
-11-
<PAGE>
make, have made, use, export, import, offer to sell, sell, distribute and
have distributed, copy, modify, assemble, disassemble, translate, compile,
decompile and make derivatives of the software, any derivative thereof or any
portion thereof embodied in the Systems and Software Products listed on
SCHEDULE 1 and of any Vysis technical information related thereto. Such
license shall be exclusive in the Cytogenetic and the Pathology Field,
exclusive for karyotyping in all fields, non-exclusive in all other fields,
but shall not include the field of array imaging. Such license shall be
revocable until, but shall become irrevocable upon, the receipt by Vysis of
all of the consideration, including any interest due, to be paid to Vysis by
AI under Section 3.1, subject to Section 8.3.
(b) Subject to the terms and conditions in this Agreement,
Vysis hereby grants to AI, and AI hereby accepts, a worldwide, paid-up,
transferable, exclusive license to make, have made, use, export, import, offer
to sell, sell, distribute and have distributed, copy and make derivatives of any
of the advertising materials and brochures, customer lists and addresses, sales
and technical service records used in the Business. Such license shall be
revocable until, but shall become irrevocable upon, the receipt by Vysis of all
of the consideration, including any interest due, to be paid to Vysis by AI
under Section 3.1, subject to Section 8.3.
(c) Subject to the terms and conditions in this Agreement,
Vysis hereby grants to AI, and AI hereby accepts, a worldwide, paid-up,
transferable, exclusive license for use of the SpectraVysion, PathVysion, all
Spectrum-branded trademarks in the Cytogenetic and Pathology Field on digital
imaging software and instrumentation, provided that (i) Vysis shall have the
worldwide right to use and sublicense such trademarks in Vysis' reagent
business, (ii) Vysis shall have the worldwide right to use and sublicense the
Spectrum-branded trademarks in instrumentation. AI shall have the right to
assign any of the trademark rights discussed herein. Vysis hereby grants to AI
and AI accepts, permission to use the phrase "Vysis-compatible" (or words
expressing such concept) in conjunction with the promotion of the systems and
products transferred hereunder. AI agrees that any software and instrumentation
marked with such trademarks that it sells or distributes for consideration shall
meet the quality assurance standards established by Vysis for Vysis'
SpectraVysion and PathVysion, which standards are attached hereto as EXHIBIT E.
Vysis warrants that its current revisions of SpectraVysion and PathVysion
software currently and consistently meet such standards as of the Closing Date.
Such license shall be revocable until, but shall become irrevocable upon, the
receipt by Vysis of all of the consideration, including any interest due, to be
paid to Vysis by AI under Section 3.1, subject to Section 8.3.
(d) Subject to the terms and conditions in this Agreement,
Vysis hereby grants to AI, and AI hereby accepts, a limited term, worldwide,
paid-up, non-transferable, non-exclusive license for use of any Vysis trademark
listed in SCHEDULE 6 in the Cytogenetic and Pathology Fields in conjunction with
its marketing and sales of the Systems and Software Products listed on
SCHEDULE 1 and its use of the advertising materials of the Business acquired
hereunder. This license is limited to a period of one year past the Closing
Date. AI agrees that during the term of this license the Systems and Software
Products listed on SCHEDULE 1 and sold by AI shall meet the quality assurance
standards established by Vysis (set forth on EXHIBIT E) for the particular
Vysis' Systems and Software Product, including the performance specifications
for use with Vysis' DNA probes. Vysis warrants that its current revisions of
QUIPS software currently and consistently meet such standards as of the Closing
Date.
-12-
<PAGE>
(e) The grant of the license in Section 7.1(a) is subject to
Vysis' retained worldwide, royalty-free, transferable right to make, have made,
use, export, import, offer to sell, sell, distribute and have distributed, copy,
modify, assemble, disassemble, translate, compile, decompile and make
derivatives of the software, any derivative thereof or any portion thereof
embodied in the Systems and Software Products listed on SCHEDULE 1 and of any
Vysis technical information related thereto: [*]
(f) The grant of the license in Section 7.1(b) is subject to
Vysis' retained worldwide, royalty-free, transferable right to make, have made,
use, export, import, offer to sell, sell, distribute and have distributed, copy
and make derivatives of any Books and Records and any of such advertising
materials and brochures, customer lists and addresses, sales and technical
service records in its retained businesses.
(g) The grant of the license in Section 7.1(c) is subject to
Vysis' retained worldwide, royalty-free, transferable right to use the
SpectraVysion trademark on (i) any reagent product sold or distributed for
consideration in any field of use, and (ii) any software or instrumentation
product using any of Vysis' retained rights in Section 7.1(d).
(h) Vysis shall be entitled to sublicense any of its retained
rights under Sections 7.1(e), (f) and (g), unless otherwise indicated to the
contrary herein.
7.2 LIMITATIONS.
(a) The licenses granted from Vysis to AI in Section 7.1 are
limited to the rights expressly granted therein and do not include: (i) any
technical information relating to any reagent product or to any digital imaging
and analysis software not listed on SCHEDULE 1 or (ii) a license to any other
Vysis Intellectual Property Rights not being sold or expressly licensed to AI
hereunder.
(b) This Agreement shall not be construed as creating any
restriction upon Vysis' research, development, clinical trials, marketing, sale
and collaborative efforts for any reagent product.
(c) AI acknowledges that certain software licensed to AI in
Section 7.1 is co-owned by Vysis and Digital Scientific, Ltd. and that beginning
January 1, 2000, Digital Scientific will have the right to exploit commercially
its rights in such software, including the grant of licenses.
7.3 COVENANT NOT TO SUE. Subject to the terms and conditions in this
Agreement, Vysis hereby agrees not to assert any claim or bring any suit, now or
in the future, against AI on the basis that its sale of the Systems and Software
Products listed in SCHEDULE 1 or AI's instrumentation products as presently
configured infringes, contributorily infringes, or induces the infringement of
any patent owned or controlled by Vysis, provided that this covenant shall not
extend to any patent right licensed to AI under its CGH license agreement with
Vysis effective January 1, 1998.
ARTICLE 8 COVENANTS WITH RESPECT TO MANUFACTURING
8.1 TRAINING. Within thirty (30) days of the Closing Date, Vysis
shall provide, at its sole cost and expense, for up to three (3) employees of AI
designated by AI, on-site manufacturing
-13-
<PAGE>
training at Vysis' Downers Grove site. AI shall bear all expenses of its
employees in connection with such on-site training.
8.2 MANUFACTURING. For the period from the Closing Date through
September 30, 1999, Vysis agrees that, if requested to do so by AI, it will
manufacture in a timely manner, and sell to AI at Vysis' standard cost, which
AI will pay within thirty (30) days of receipt of an invoice therefor, any of
the Systems and Software Products listed on SCHEDULE 1.
8.3 [*]
(a) Vysis agrees to complete the development of its [*]
product in accordance with its existing procedures for completion and release
of a product for sale. This development will be of the product as specified
in Vysis' existing marketing essential characteristics ("MEC") without change
in the MEC. The [*] detailed MEC product specifications and project schedule
for completion are attached as EXHIBIT F. Vysis, will use its best efforts
and resources for completion of the product according to the schedule shown
in EXHIBIT F. In the event the [*] product is not completed according to
schedule, (i) Vysis shall continue to devote no less than the level of
resources, on a best efforts basis, as had previously been devoted to
completion of the product pursuant to the schedule in EXHIBIT F, and (ii) AI
shall have the right, on the scheduled twelve (12) month payment date
pursuant to Section 3.1(a) of this Agreement, without regard to adjustments
as provided for below, to request copies of all source code, all systems
specifications and documentation complete as of the date of request, which
request shall be fulfilled within ten (10) days of such request, and AI shall
have the unrestricted right to commercially or otherwise utilize such source
code, specifications and documentation, provided however, that any
modification of such code by AI shall have no affect on the finished [*]
product to be delivered by Vysis to AI. In the event the [*]product is not
delivered by December 31, 1999, then AI's one year anniversary and eighteen
month anniversary payments under Section 3.1(a) shall be delayed one day for
each day the final [*] product completion and delivery are delayed past
December 31, 1999. Any delay in payments under Section 3.1(a) due to this
provision shall be on an interest-free basis and shall in no way affect the
validity of any license or be the basis for termination of any license
granted to AI under this Agreement. Completion of the [*] product shall be
that the MECs have been fulfilled as measured by the criteria attached hereto
as EXHIBIT F which will include at least one customer beta site test. All
expenses of the [*] product development will be the responsibility of Vysis.
To facilitate and complete the transfer of the [*] product pursuant to this
Agreement, Vysis shall make available during the thirty (30) day period
following delivery of the [*] product, the research and development staff
associated with the development of the Vysis [*] project for the training of
AI staff for up to ten (10) days' intensive training, the cost of which shall
be borne by AI.
(b) AI shall have the right to review the MEC and to request
changes in the MEC, but AI will be responsible for any additional development
expense resulting from such changes, as determined by Vysis provided that
Vysis shall not be penalized for any delay in the [*] delivery schedule
incident to any such requested change by AI.
-14-
<PAGE>
8.4 ACCESS TO RESEARCH RECORDS AND TECHNICAL INFORMATION.
(a) Vysis will make its U.S. based personnel with knowledge of
its research efforts in the Business available at Vysis' Downers Grove facility
to AI as reasonably requested by AI on at least 48 hours' notice, to assist AI
in the transition of the Business. This access shall not unduly interfere with
Vysis' ongoing research and development in its retained businesses and the [*]
development.
(b) For sixty (60) days after the Closing Date, Vysis will
provide reasonable access during normal business hours at Vysis' Downers Grove
facility to AI to review and copy at AI's expense any of the research records,
including computer records, of Vysis' software development group that relate to
the Systems and Software Products listed on SCHEDULE 1. This access shall not
unduly interfere with Vysis' ongoing research and development in its retained
businesses and the [*] development.
8.5 CONTRACTS, LICENSES AND SERVICE AGREEMENTS. Vysis hereby assigns
to AI all its right and interest in and to all Contracts, Licenses and Service
Agreements listed on SCHEDULES 2, 4 AND 5, respectively. AI and Vysis shall
cooperate in notifying the other party to such Contracts, Licenses and Service
Agreements and to secure any consents necessary to effectuate the assignment.
8.6 ASSUMPTION OF CONTRACT OBLIGATIONS.
(a) AI hereby assumes all Vysis' obligations under the
Contracts, Licenses and Service Agreements, copies of which have been
provided to AI.
(b) AI hereby assumes all Vysis warranty obligations for the
Systems and Software Product installations listed on SCHEDULE 9, attached and
incorporated herein, that are to be performed subsequent to the Closing Date.
(c) A list of all warranty and service contracts and
obligations being assumed hereunder is attached on SCHEDULE 11.
(d) Vysis shall be responsible for System and Software
Product returns for sales made by Vysis before the Closing Date for a period
of ninety (90) days' post closing with AI responsible thereafter, and AI
shall be responsible for System and Software Product returns for sales made
by AI after the Closing Date.
8.7 EMPLOYMENT. In order to facilitate a smooth transfer of the
Business and to further the purposes of this Section 8.7 and this Agreement,
Vysis shall use its best efforts to encourage and promote the acceptance of any
offers made by AI to Vysis employees pursuant to this Agreement. For a period
of 24 months after the Closing, Vysis agrees that it shall not directly or
indirectly solicit, induce, recruit, or encourage any of its former employees
(whether AI employees or otherwise) to leave their employment either for
employment at Vysis or at another person or entity, except for those persons
involved in the research and development of the Business.
(a) In connection with the transfer of the Business, AI shall
have the right to solicit the research (2 U.S.), technical service (2 U.S. and 4
Europe), and sales (1 U.S.) employees of
-15-
<PAGE>
Vysis who are identified on SCHEDULE 11 attached hereto. AI agrees to
consider such employees for employment and to make any offers of employment
within sixty (60) days of the Closing Date. Vysis agrees that the employees
listed on SCHEDULE 11 may be employed by and provide services to AI;
provided, that Vysis will continue to enforce the proprietary,
confidentiality and similar provisions in any agreements with such employees
to the extent such enforcement relates to information not used in the
Business as of the Closing Date. The human resources departments of the
parties will cooperate in the hiring of any such employee by AI. In regards
to the employment offers which AI will make to the four members of Vysis'
Europe based technical service employees, in the event that one or more such
offers are not accepted, Vysis, at AI's request, shall continue the
employment of such employee(s) for the benefit of AI and at AI's expense, for
a period of up to six months beyond the sixty day anniversary of the Closing.
In regards to the employment offers which AI will make to the two U.S. based
research employees, in the event that one or more such offers are not
accepted, Vysis, at AI's request, shall continue the employment of such
employee(s) for the benefit of AI and at AI's expense, for a period of up to
four months beyond the delivery of the [*] product.
(b) The hiring of employees of Vysis shall be at the sole
discretion of AI, and AI shall have no obligation to make offers of employment
to any person. As between the parties, all rights to accrued vacation, to any
severance payments and to all other rights of employees of Vysis created upon
the termination of their employment with Vysis shall remain the sole
responsibility of Vysis. AI agrees that it shall treat the years of service
with Vysis of any Vysis employee hired by AI as years of service with AI for
purposes of calculating vacation and other employee benefits of AI.
ARTICLE 9 GENERAL COVENANTS
9.1 ACCESS AND RIGHTS OF INSPECTIONS. For thirty (30) days after the
Closing Date, Vysis will allow AI and its counsel, accountants, consultants and
other representatives reasonable access, during normal business hours and so as
not to unreasonably interfere with the business operations of Vysis, to all
properties, Contracts, books and records, including technical service records
used in or relating to Vysis' operation of the Business.
9.2 FURTHER ASSURANCES. Both before and after the Closing, each
party hereto agrees to execute, acknowledge and deliver such further instruments
and to do all such other acts as may be necessary or appropriate in order to
carry out the purposes and intents of this Agreement. Without limiting the
foregoing, AI agrees that it will, both prior to and after the Closing, without
demanding or receiving any further consideration, at the request of Vysis,
perform any and all legal acts, including the execution and acknowledgment of
instruments, that may be or become necessary or convenient for effectuating the
assignment of any property assigned hereunder.
9.3 CLAIMS HANDLING. Vysis and AI agree to cooperate concerning the
handling of any claims, tax, government reporting, government investigation or
litigation matters arising after the Closing Date and relating to the Business.
9.4 [*] Vysis and AI will review AI's [*] product line for possible
distribution by Vysis of the [*] products as part of Vysis' reagent business.
Any such possible distribution will be
-16-
<PAGE>
pursuant to a written product distribution agreement to be negotiated between
the Parties and entered into separately from this Agreement.
9.5 CONFIDENTIALITY REGARDING INFORMATION OF BUSINESS.
(a) Vysis agrees that, after the Closing, it shall not disclose
to any person or entity not employed by, or not engaged to render services to,
Vysis, any trade secrets, financial data, operational methods, customer lists,
marketing and sales information or other proprietary information relating to the
Business, except in conjunction with the operation of its retained businesses or
its retained rights under Section 7.1 and under the conditions used by Vysis to
protect its own business information and except for purposes of SEC filings.
(b) AI agrees that, after the Closing, it shall not disclose to
any person or entity not employed by, or not engaged to render services to, AI,
any trade secrets, financial data, operational methods, customer lists,
marketing and sales information or other proprietary information relating to the
Business, except in conjunction with the operation of Business or exercise of
its rights under Section 7.1 and under the conditions used by AI to protect its
own business information and except for purposes of SEC filings.
9.6 COVENANT NOT TO COMPETE.
(a) In connection with the transfer of the Business to AI, for
the period from the Closing Date until the fifth anniversary of the Closing
Date, Vysis will not compete with AI anywhere in the world in the marketing and
sale of stand-alone cytological digital imaging systems in the Cytogenetics and
the Pathology Fields; provided that Vysis': [*]
(b) AI acknowledges that this non-compete covenant shall not be
construed as violated by any research and development activities of Vysis either
internal or with third party collaborators. AI further acknowledges that this
non-compete covenant shall not be construed as violated by Vysis' performance of
its agreement with Digital Scientific, including any contractually required
transfer of source code to Digital. Section 9.1 shall not preclude Vysis from
holding, as a passive investment, not more than five percent (5%) of any class
of securities, which class is publicly traded on a U.S. securities exchange or
the Nasdaq National Market, of any corporation, partnership, business or other
entity with operations directly competitive with AI.
9.7 COMPATIBILITY OF REAGENTS. AI agrees to use reasonable commercial
efforts, within 60 to 90 days before product launch if possible, to provide
Vysis with information related to modifications of the products listed in
SCHEDULE 1 for Vysis' internal use to ensure compatibility of its reagents with
such products, including three copies of any software developed by AI for Vysis'
use in its reagent research.
ARTICLE 10 SURVIVAL OF REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION;
ARBITRATION
10.1 INDEMNIFICATION BY VYSIS. Vysis shall indemnify and hold harmless
AI and its Affiliates against any and all claims (including product liability
and personal injury claims), demands, actions, proceedings, liabilities, losses,
damages, costs and expenses, including, without
-17-
<PAGE>
limitation, reasonable expert witness and attorneys' fees and costs which may
be asserted against or incurred by AI or its Affiliates, arising out of or
related to (a) any claim or suit by a third party which is based upon a
breach of any of the representations or warranties made by Vysis in Article
4, (b) any claim or suit which is based upon the conduct of the Business
before the Closing Date (except for liabilities expressly assumed by AI
hereunder and set forth as Assumed Liabilities in SCHEDULE 9 hereto), and (c)
any breach by Vysis of its obligations or covenants hereunder.
10.2 INDEMNIFICATION BY AI. AI shall indemnify and hold harmless Vysis
and its Affiliates against any and all claims (including product liability and
personal injury claims), demands, actions, proceedings, liabilities, losses,
damages, costs and expenses, including, without limitation, reasonable expert
witness and attorneys' fees and costs which may be asserted against or incurred
by Vysis or its Affiliates, arising out of or related to (a) any claim or suit
by a third party which is based upon a breach of any of the representations or
warranties made by AI in Article 5, (b) any claim or suit by a third party which
is based upon the conduct of the Business after the Closing Date, and (c) any
breach by AI of its obligations or covenants hereunder.
10.3 PROCEDURE. The indemnified party will: (a) promptly notify the
indemnifying party of any claim, suit or proceeding for which defense or
indemnity is claimed; (b) cooperate reasonably with the indemnifying party at
the latter's expense; and (c) allow the indemnifying party to control the
defense or settlement thereof, provided, however, that the indemnifying party
may not consent to entry of any judgment or enter into any settlement without
the prior written consent of the indemnified party (which consent shall not
be unreasonably withheld or delayed), unless such judgment or settlement
provides solely for money damages or other money payments which the
indemnifying party actually pays on behalf of the indemnified party and
includes as an unconditional term thereof a release of the indemnified party
from all liability in respect of the claim, suit or proceeding giving rise to
the claim for indemnification. The indemnified party will have the right to
participate in any defense of a claim and/or to be represented by counsel of
its own choosing at its own expense.
10.4 INDEMNITY LIMIT. Vysis' obligation to indemnify AI, and AI's
obligation to indemnify Vysis hereunder, shall each not exceed a total
expenditure, for any and all claims, demands, actions, proceedings,
liabilities, losses, damages, costs and expenses, of [*], except for claims,
demands, actions, proceedings, liabilities, losses, damages, costs and
expenditures which are the result of fraud or intentional non-disclosure on
the part of Vysis are not subject to any dollar limitation on Vysis'
obligation to indemnify AI hereunder. For any and all claims, demands,
actions, proceedings, liabilities, losses, damages, costs and expenses
incurred by AI in matters related to the establishment, preservation, or
defense of title to the Assets transferred or licensed under this Agreement,
Vysis' obligation to indemnify AI shall be limited to [*].
10.5 DISCLAIMER. Except as expressly set out in this Agreement and
except for any warranties implied by law, Vysis makes no additional warranties
or guarantees. Vysis makes no warranty or guarantee to AI concerning the
accuracy of any business or research records provided to AI pursuant to the
terms of this Agreement.
-18-
<PAGE>
10.6 SURVIVAL OF WARRANTIES. Any claim for indemnification hereunder,
except for claims based on fraud or intentional non-disclosure by Vysis, must be
made on or prior to December 31, 2000. Any claim not noticed by December 31,
2000, shall be irrevocably waived and released.
10.7 LIMITATION OF LIABILITY. IN NO EVENT SHALL ANY PARTY BE LIABLE TO
THE OTHERS FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES,
HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, ARISING OUT OF THIS AGREEMENT,
WHETHER OR NOT SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, EXCEPT
FOR INSTANCES INVOLVING FRAUD AND INTENTIONAL NON-DISCLOSURE, AND EXCEPT WHERE
SUCH IS ALLEGED BY A THIRD PARTY CLAIMANT FOR WHICH ONE OF THE PARTIES HERETO IS
ENTITLED TO INDEMNIFICATION HEREUNDER.
ARTICLE 11 MISCELLANEOUS
11.1 SUCCESSORS; ASSIGNABILITY. Either party may assign its rights
hereunder without the consent of the other party. This Agreement shall inure to
the benefit of and be binding upon the executors, administrators, successors and
permitted assigns of the parties hereto.
11.2 COSTS AND EXPENSES. Whether or not the transactions contemplated
by this Agreement are consummated, Vysis will pay its own expenses, and AI will
pay its own expenses, in connection with the negotiation, execution, delivery
and performance of this Agreement, including without limitation the expenses of
their respective counsel, accountants and other experts.
11.3 OTHER AGREEMENTS SUPERSEDED; WAIVER AND MODIFICATION, ETC. This
Agreement supersedes all prior agreements or understandings, written or oral,
between the parties relating to the subject matter hereof, and incorporates the
entire understanding of the parties with respect to such subject matter. This
Agreement may be amended, supplemented or waived only by a written instrument
signed by an authorized representative of both parties. The parties expressly
acknowledge and agree that, except for the licenses expressly granted AI in
Section 7.1 and the assignment of Intellectual Property Rights pursuant to
Section 3.4, no other rights of any kind to the Intellectual Property Rights
owned by Vysis or its third-party licensors (including, without limitation,
implied licenses) are granted to AI under this Agreement, except those rights
that accompany the Acquired Assets. AI hereby expressly disclaims any implied
licenses under any patents held by Vysis and/or its licensor, The Regents of the
University of California.
11.4 OVERDUE PAYMENTS. Any amount payable under this Agreement which
is not paid when due shall bear interest at the lower of (a) an annual rate of
18% and (b) the highest rate allowed by law.
11.5 NOTICES. Any notice under or relating to this Agreement shall be
given in writing and shall be deemed sufficiently given and served for all
purposes (a) when personally delivered or transmitted by facsimile, or (b) two
(2) business days after a writing is deposited in the United States mail, first
class postage or other charges prepaid and registered, addressed as follows:
(a) If to Vysis:
-19-
<PAGE>
3100 Woodcreek Drive
Downers Grove, Illinois 60515
Attention: President & CEO
Facsimile: (630) 271-7078
(b) If to AI:
2380 Walsh Avenue, Building B
Santa Clara, California
Attention: President & CEO
Facsimile: (408) 562-0264
11.6 PARTIES IN INTEREST. Nothing in this Agreement, express or
implied, is intended to confer any rights or remedies under or by reason of this
Agreement on any Person other than the parties to it and their respective
permitted successors and assigns, nor is anything in this Agreement intended to
relieve or discharge any obligation of any third Person to any party hereto or
give any third Person any right of subrogation or action over against any party
hereto.
11.7 GOVERNING LAW; JURISDICTION. This Agreement shall be construed in
accordance with and governed by the laws of the State of California, without
giving effect to the principles of conflict of laws thereof.
11.8 FAIR CONSTRUCTION/DIFFERENCE IN FACTS. This Agreement has been
negotiated and prepared jointly by both parties and shall not be construed for
or against any party but shall be given a fair and reasonable construction in
accordance with the intention of the parties.
11.9 CAPTIONS, REFERENCES, DATE. The Article and Section headings in
this Agreement are provided for convenient reference only and are not to be
considered in the interpretation of this Agreement. All references herein to
Article, Section, Schedule, etc. refer to the designated Article, Section,
Schedule, etc. of this Agreement.
11.10 SEVERABILITY. In the event that any of the provisions contained
in this Agreement shall, for any reason, be declared or held to be unreasonable,
unlawful, unenforceable or otherwise invalid in any respect, such term or
provision shall be deemed modified to the extent necessary to make it
enforceable, and in no event shall such declaration or holding affect the
validity of any other provision of this Agreement, all of which provisions shall
continue in effect in accordance with their terms.
11.11 COUNTERPARTS. This Agreement may be executed in any number of
counterparts or using separate signature pages. Each such executed counterpart
and each counterpart to which such signature pages are attached will be deemed
to be an original instrument, and all such counterparts together will constitute
one and the same instrument.
11.12 RECOVERY OF LITIGATION COSTS. If any legal action or any
arbitration or other proceeding is brought for the enforcement of this
Agreement, or because of an alleged dispute, breach, default or
misrepresentation in connection with any provision of this Agreement, the
-20-
<PAGE>
successful or prevailing party shall be entitled to recover reasonable
attorneys' fees and other costs incurred in that action or proceeding, in
addition to any other relief to which it may be entitled.
11.13 RELATIONSHIP OF THE PARTIES. Both parties are independent
contractors under this Agreement. Nothing contained in this Agreement is
intended nor is to be construed so as to constitute Vysis and AI as partners
or joint ventures with respect to the subject matter of this Agreement.
Neither party hereto shall have any express or implied right or authority to
assume or create any obligations on behalf of or in the name of the other
party or to bind the other party to any other contract, agreement or
undertaking with any third party.
11.14 BROKERAGE. Each party represents and warrants to the other that
it has dealt with no broker or finder in connection with any of the transactions
contemplated by this Agreement and, insofar as each party knows, no broker,
finder or other Person is entitled to any brokerage commission or finder's fee
in connection with any of such transactions. Each party agrees to indemnify and
hold harmless the other from and against any loss or damage incurred by reason
of any other brokerage commission or finder's fee alleged to be payable because
of any act, omission or statement of the indemnifying party.
11.15 PUBLICITY.
(a) Upon the Closing, Vysis and AI each shall issue the press
announcement attached as EXHIBIT G hereto.
(b) Vysis and AI may each be required to attach this Agreement
as an exhibit to documents required to be filed with the Securities Exchange
Commission pursuant to the Securities Act of 1933 and the Securities Exchange
Act of 1934, each as amended. Vysis and AI shall cooperate in determining
whether confidential treatment should be sought for all or any part of such
filings, and, if it is agreed that confidential treatment should be sought, each
party shall use reasonable best efforts to secure such confidential treatment.
(c) The Parties will cooperate on any other announcement where
the name of the other Party is used in a way not expressly authorized under this
Agreement.
11.16 ARBITRATION. Any claim arising out of or related to this
Agreement shall be finally settled by arbitration in the County of Denver,
Colorado in accordance with the then current Commercial Arbitration Rules of the
American Arbitration Association; and judgment upon the award rendered by the
arbitrator may be entered in any court having jurisdiction thereof. Such
arbitration shall be conducted by an arbitrator chosen by mutual agreement of AI
and Vysis. Failing such agreement, the arbitration shall be conducted by three
independent arbitrators, none of whom shall have any competitive interests with
AI or Vysis. AI shall choose one such arbitrator, Vysis shall choose one such
arbitrator, and such two arbitrators shall mutually select a third arbitrator.
Any decision of two such arbitrators shall be binding on AI and Vysis. Each
party shall pay its own costs and expenses (including counsel fees) of any such
arbitration except that the arbitrator must compel the non-prevailing party to
pay all of the prevailing party's costs and expenses.
11.17 SOLE REMEDY. Except for the rights of the Parties to injunctive
relief for violations of Sections 9.5 and 9.6 the indemnification provided in
Section 10 hereof (subject to the limitations
-21-
<PAGE>
contained therein) shall be the sole and exclusive remedy for any and all
matters arising out of, or related to, this Agreement.
(REMAINDER OF PAGE LEFT BLANK INTENTIONALLY)
-22-
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Asset Transfer
Agreement to be effective as of the date first written above:
VYSIS, INC.
By:
/s/ R. Williams
--------------------------
Name: Richard Williams
Title: Co-Chairman
APPLIED IMAGING CORP.
By:
/s/ J. Goldstein
----------------------------
Name: Jack Goldstein
Title: President & CEO
-23-
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-START> JAN-01-1999
<PERIOD-END> JUN-30-1999
<CASH> 1,680
<SECURITIES> 8,445
<RECEIVABLES> 6,988
<ALLOWANCES> (1,419)
<INVENTORY> 2,797
<CURRENT-ASSETS> 19,936
<PP&E> 12,090
<DEPRECIATION> (8,582)
<TOTAL-ASSETS> 25,457
<CURRENT-LIABILITIES> 8,814
<BONDS> 691
0
0
<COMMON> 10
<OTHER-SE> 16,403
<TOTAL-LIABILITY-AND-EQUITY> 25,457
<SALES> 11,637
<TOTAL-REVENUES> 11,916
<CGS> 4,686
<TOTAL-COSTS> 18,348
<OTHER-EXPENSES> 541
<LOSS-PROVISION> 129
<INTEREST-EXPENSE> 50
<INCOME-PRETAX> (6,296)
<INCOME-TAX> 0
<INCOME-CONTINUING> (6,296)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (6,296)
<EPS-BASIC> (0.64)
<EPS-DILUTED> (0.64)
</TABLE>
